SECTION I: GUIDELINES FOR CANCER DATA REPORTING

The Florida Cancer Data System (FCDS) is charged with maintaining a high quality database of useable, timely, complete and accurate clinical data for every reportable case of cancer diagnosed or treated in the state of Florida. The FCDS Data Acquisition Manual (FCDS DAM) includes guidelines and instructions for case identification, case eligibility (which cases must be reported to FCDS), abstracting and coding, and multiple appendices that are referenced throughout the manual. The manual only addresses data items that are required by FCDS, the Florida Department of Health (DOH), and the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR) to support Florida’s statewide, population-based cancer registry. These guidelines have been established as a means to achieve and maintain this objective.

All reporting facilities, regardless of affiliation, MUST adhere to the following guidelines for cancer data reporting. The instructions and codes in this manual take precedence over all previous instructions/manuals.

It is the responsibility of the reporting facility and the facility abstractor (contractor) to be familiar with and understand the content of the most current version of the FCDS Data Acquisition Manual and to update it upon receipt of any changes from FCDS. This responsibility exists without regard to whether or not case abstracting and reporting is being performed by an employee of the reporting facility or through some contractual arrangement with an independent abstracting agency or individual within or outside the state of Florida.

CONFIDENTIALITY - Patient information, personal health information, medical records and healthcare facility data are all confidential and continue to be a concern with regard to cancer and other disease reporting. Please do not fax or email patient information to FCDS. Also, please take care when discussing cases over the phone with FCDS staff.

DO NOT E-MAIL, FAX OR MAIL PATIENT INFORMATION (PHI) TO FCDS UNDER ANY CIRCUMSTANCES unless you are provided specific instructions for using our Secure Fax Service.

A. CASE ELIGIBILITY

Florida facilities are legislatively mandated to report any case of cancer meeting the Florida “cancer” definition, regardless of facility or network affiliation or Class of Case. FCDS requires complete abstracting of additional select neoplasms that the Commission on Cancer/American College of Surgeons does not require such as benign and borderline brain and central nervous system tumors and certain reproductive site cancers.

The 2018 Updates to National Standards incorporate several new histologic types, subtypes, and changes to behaviors making some cancers new to state reportable due to reclassification by WHO as “malignancy”.

If your facility participates in the diagnosis, staging, treatment, or continuing care of a patient during the first course of treatment, progression of disease or disease recurrence the case must be reported to FCDS.

If any diagnostic, staging, or other evaluative studies are conducted at your facility (diagnostic imaging, re-biopsy, sentinel node biopsy, surgical resection or other staging or treatment, etc.) your facility must report the case regardless of the Class of Case. Please review all standard cancer diagnosis codes and procedures codes.

Patients whose “First Course of Therapy” is “Active Surveillance” or “Watchful Waiting” must be reported as their cancer has been diagnosed but will not be treated by any means, until or unless the patient has clinical symptoms, imaging, or laboratory evidence of progression of disease. This treatment decision is usually for non-aggressive neoplasms and very early stage cancers that do not meet the standard threshold for active treatment.

A decision by the patient and/or their family that the patient receive “NO TREATMENT” is a different treatment decision than “Watchful Waiting” and is not to be coded as cancer treatment or treatment given. Please be cautious when distinguishing the two very different types of cases. These cases are usually patients with advanced or untreatable disease or when the patient has other comorbid factors that prohibit cancer tx.
“Consult-Only” and “Second Opinion” cases MAY be an exception to reporting depending upon what took place at the facility to confirm a diagnosis or establish or confirm the validity of a proposed treatment plan. Some second opinions/consultations include the ordering of new laboratory and/or imaging tests. Anytime a new test is ordered by your facility – the case is no longer a consult only…even if that is the only test done. Other second opinion/consults include only a review of tests already performed elsewhere.

A true “consult only” or “second opinion” case is any case where the facility provides a second opinion or expert panel review of earlier performed diagnostic or workup studies without additional testing at your facility. A second opinion may include re-reading pathology slides or re-reading diagnostic imaging studies.

If your facility does not perform any additional testing, the case may not be reportable to FCDS. However, if your facility does perform any additional testing for this or any other cancer and they have evidence of active disease or if they are undergoing treatment for cancer at any facility, the case is reportable to FCDS.

**Exception 1:** Patients undergoing planned first course or later course long-term hormonal treatment for breast or prostate cancer that continue to demonstrate no active neoplasm should not be reported. Any other type of cancer or patient with active malignancy (any evidence of disease) must be reported.

**Exception 2:** Patients seen in an ambulatory care setting for “port-a-cath” placement only where no chemotherapeutic or anti-neoplastic agent(s) is injected into the port do not need to be reported.

Many Florida healthcare facilities including Commission on Cancer/American College of Surgeons accredited cancer programs who wish to track “port-a-cath” placement visits do continue to report these cases voluntarily as part of monitoring the full continuum of patient care available and monitored under the care of the facility.

Please note that many types of drugs may be administered through a “port-a-cath” delivery system. The medical record and medication flow sheets MUST be reviewed and cannot include administration of any anti-neoplastic agent(s) through the port-a-cath for the case to meet this exclusion criterion. If any anti-neoplastic agent is administered at the reporting facility, either as an outpatient or inpatient, the case must be reported.

**Note:** Facilities may opt to abstract and report “port-a-cath” placement only cases at their discretion. It is up to a formal decision by your Cancer Committee (if you have one) to include or not include these “port-a-cath” only cases. You must consult the Cancer Committee at your facility and document this decision in committee meeting minutes and in any facility procedures manuals. Please include the date that you stopped reporting.

1. **Reportable Patients**

   All patients first seen at the reporting facility on or after January 1, 1981 (July 1, 1997 for freestanding/ambulatory surgery centers and freestanding radiation therapy centers), whether as an inpatient, outpatient or in an ambulatory care setting, who meet one or more of the below criteria must be reported to FCDS. Any cancer patient not reported will be included in QC Audits for review. The start date for your registry for the state of Florida is 1/1/1981 or the day your facility opened. It is not the same start date that the Commission on Cancer assigns your facility. All reporting began in 1981.

   a) all patients with an active, malignant neoplasm (in-situ or invasive), whether being treated or not (includes “active surveillance” cases) – with limited exceptions such as CIN III and PIN III,
   
   b) all patients with an active, benign or borderline brain or central nervous system (CNS) tumor, diagnosed on or after 01/01/2004, whether being treated or not (includes active surveillance)
   
   c) all patients undergoing prophylactic, neoadjuvant, or adjuvant therapy for malignancy,
   
   d) all patients undergoing ‘active surveillance’ or ‘watch and wait’ approach to therapy,
   
   e) patients seen as in-patient, out-patient, or in-clinic are reportable,
   
   f) all patients diagnosed at autopsy,
   
   g) all historical cases that meet FCDS reportable guidelines.
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

2. Not Reportable Patients

a) patients in remission (NED) and not receiving prophylactic or adjuvant therapy,
b) patients seen only in consultation to provide a second opinion to confirm a diagnosis or a
   treatment plan (no additional testing can be performed at your facility or the case is reportable),
c) patients first seen at the reporting facility prior to January 1, 1981 (July 1, 1997 for free-standing
   centers) and returning after that date for treatment of the same primary malignant neoplasm,
d) patients who receive transient care to avoid interrupting a course of therapy started elsewhere.

3. Reportable Neoplasms

Determination of whether or not a given primary neoplasm is reportable is made by reference to the
histology and behavior codes of the International Classification of Diseases for Oncology, 3rd ed.,
including approved updates and errata published by WHO and approved by NAACCR for ICD-O-3.

There have been numerous new publications by the WHO of the 4th edition “Blue Books” (and WHO
Published Updates to 4th ed.) which are the worldwide accepted versions of the WHO Classification of
Neoplasms are the primary resource for all old and new ICD-O-3 Codes/Terms/Conditions.

The 2011 ICD-O-3 Updates included new classification groupings, new codes, new terms, and
changes to neoplasm behavior identified from the WHO “Blue Books” published since the original
ICD-O-3 Manual was published. The basis of changes included:

WHO Classification of Tumors of the Central Nervous System (2007)
WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues (2008
WHO Classification of Tumors of the Digestive System (2010)

Many of the 2011 ICD-O-3 Updates have been incorporated into the SEER Hematopoietic and
Lymphoid Neoplasm Case Reportability and Coding Manual and Database. (Please refer to the most
current version of the Hematopoietic Database and Manual for complete reporting instructions.)

Additional revisions to terms, codes, and conditions have been introduced for 2018. Please refer to the
published 2018 ICD-O-3 Updates for all US approved updates to ICD-O-3 Codes, Terms, and more.
The 2018 basis for new and updated histology codes, behavior codes, terms and conditions include:

WHO Classification of Tumors of the Breast (2010)
WHO Classification of Tumors of the Female Reproductive Organs (2013)
WHO Classification of Tumors of Soft Tissue and Bone (2013)
WHO Classification of Tumors of the Lung, Pleura, thymus, and Heart (2015)
WHO Classification of Tumors of the Urinary System and Male Genital Organs (2016)
WHO Classification of Tumors of the Central Nervous System, Revised 4th Ed (2016)
WHO Classification of Tumors of Endocrine Organs, Revised 4th Edition (2017)

An online version of ICD-O-3 is available on the WHO International Agency for Research on Cancer
(IARC) website: http://codes.iarc.fr/. This online tool should be used with caution as it contains some
changes that have not been adopted by the United States for the 2011 and none of the 2018 Updates:

- Numerous clarifications for new classifications for specific types of neoplasms in specific
  anatomic locations and whether or not they are reportable are contained in the Guidelines
  Section I of the FCDS DAM as well as in Part II – Coding Instructions of this same manual.
- The procedure for Coding ICD-O-3 histology has changed for both hematopoietic neoplasms
  (use the Heme DB) and for solid tumors use the 2018 Solid Tumors MPH Rules and DB.
- Please reference Part II – Coding Instructions for 2018 instructions to code histology as well
  as the associated appendices and external tools and rules for new and specific codes available

Revised 2018
and instructions for using the new codes. See Part II Coding Instructions & both MPH DBs.

- Use the 2018 or later version of the MPH Rules for Solid Tumors and the Solid Tumors Database to supplement the ICD-O-3 for all solid tumors diagnosed 2018 and later. The 2018 MPH rules and database already include the 2018 Solid Tumor Histology Code Updates.
- Use the 2018 or later version of the MPH Rules for Hematopoietic and Lymphoid Neoplasms and the Hematopoietic Database to identify and code any myeloid or lymphoid neoplasm (any histology code 9590/3 or greater). The 2018 MPH rules and databases already include the 2018 Heme/Lymph Histology Code Updates.

a) **In Situ and Invasive Cancers** - FCDS includes all primary malignancies - in situ and/or invasive. Therefore, any cancer with an ICD-O behavior code of /2 (in situ) or /3 (malignant) is reportable to FCDS (except carcinoma in situ of the cervix, carcinoma in situ of the prostate, CIN III, and PIN III). Cancers with benign or borderline behavior are discussed elsewhere in this section.

   If a tumor with an ICD-O behavior code of /0 or /1 is determined to be in-situ or invasive by the manner in which it is behaving (in malignant fashion), or by a pathologist, the case is reportable.

   i. **Anal Intraepithelial Neoplasia (AIN III)** is reportable to FCDS and should be included in casefinding activities. This non-invasive neoplasm of the anus or anal canal (C21.0-C21.1) is not the same as SCC of perianal skin (C44.5). It is important to distinguish between true anal cancers and skin of anus neoplasms. Neoplasms of the skin of anus (perianal skin) are not reportable, even if they extend into the anal canal. AIN III of the perianal skin is not reportable to FCDS.

   ii. **Laryngeal Intraepithelial Neoplasia (LIN III)** is reportable to FCDS and should be included in casefinding activities.

   iii. **Vaginal Intraepithelial Neoplasia (VAIN III)** is reportable to FCDS and should be included in casefinding activities.

   iv. **Vulvar Intraepithelial Neoplasia (VIN III)** is reportable to FCDS and should be included in casefinding activities.

   v. **Pancreatic Intraepithelial Neoplasia (PAIN III)** is reportable to FCDS (histology 8148/2) and should be included in casefinding activities.

   vi. **Glandular Intraepithelial Neoplasia, Grade III/High Grade Glandular Dysplasia** is reportable as adenocarcinoma in situ of the esophagus with histology code 8148/2.

   vii. **Glandular Intraepithelial Neoplasia, Grade III/High Grade Glandular Dysplasia of other colorectal sites** are not reportable unless the pathologist specifically states the tumor is ‘in-situ’ or ‘non-invasive’ or your Cancer Committee has agreed on this.

   viii. **LCIS** is reportable to FCDS and to all central cancer registries across the country. Lobular Carcinoma In-Situ (LCIS) was stated to be ‘non-malignant’ by the AJCC in the most recent AJCC Cancer Staging Manual, 8th edition. However, the World Health Organization (WHO) still classifies this histology to be an in-situ malignancy. ICD-O-3 acquires 100% of our valid histology codes only from the WHO and the WHO Guidelines.

   ix. **In Utero Diagnosis and Treatment** – beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born. The exact date may be used for cases diagnosed prior to 2009 and must be used for cases diagnosed 1/1/2009 and later.
New terminology may be used by your local pathologist to describe malignant or in situ neoplasms (i.e. well differentiated neuroendocrine neoplasm). When this occurs the neoplasm is reportable to FCDS.

*Note 1: AJCC TNM Manual, 8th edition states for Esophageal Cancers: “High grade dysplasia includes all non-invasive neoplastic epithelia that was formerly called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the gastrointestinal tract.” Therefore, all high grade/severe dysplasia of esophagus are reportable as carcinoma in situ.

*Note 2: AJCC TNM Manual, 8th edition states for Colon Cancers: “The terms ‘high grade dysplasia’ and ‘severe dysplasia’ may be used as synonymous for in situ adenocarcinoma and in situ carcinoma.” It is necessary to contact your pathologist and/or cancer committee to determine if s/he applies this definition to all colon cancers. If so, high grade/severe dysplasia of any colon site is reportable as adenocarcinoma in situ (8140/2).

b) **Specified malignant neoplasms of the skin:** dermatofibrosarcoma protubersans, Kaposi sarcoma, malignant melanoma, Merkel cell carcinoma, mycosis fungoides, sebaceous adenocarcinoma, and sweat gland adenocarcinoma are reportable conditions.

c) **Gastro-intestinal stromal tumor (GIST)** is often non-malignant, particularly when found incidentally and the patient is symptom-free. However, cases must be abstracted and assigned a Behavior Code of /3 if they are noted to be 5cm or larger in size, have a high mitotic rate/grade, present with multiple foci, metastasis, or positive lymph nodes or there is other evidence of malignancy noted by surgeon, pathologist, or during clinical workup following initial diagnosis.

d) **Chronic Lymphocytic Leukemia** patients may exhibit clinical remission (no symptoms) but are never totally free of disease. Physicians may even state these patients are “in remission”. However, these cases should be reported to FCDS, regardless of physician-stated remission status.

e) **Basal and squamous skin cancers in genital sites** (histology codes 8000-8110) are reportable. “Genital Sites” include the following anatomic locations:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C51.0</td>
<td>Labia</td>
</tr>
<tr>
<td>C51.1</td>
<td>Labia</td>
</tr>
<tr>
<td>C51.2</td>
<td>Clitoris</td>
</tr>
<tr>
<td>C51.3</td>
<td>Vulva</td>
</tr>
<tr>
<td>C51.8</td>
<td>Vulva</td>
</tr>
<tr>
<td>C51.9</td>
<td>Vulva</td>
</tr>
<tr>
<td>C52.0</td>
<td>Vagina</td>
</tr>
<tr>
<td>C60.0</td>
<td>Prepuce</td>
</tr>
<tr>
<td>C60.1</td>
<td>Penis</td>
</tr>
<tr>
<td>C60.2</td>
<td>Penis</td>
</tr>
<tr>
<td>C63.2</td>
<td>Scrotum</td>
</tr>
</tbody>
</table>

f) **Carcinoid Tumor of Appendix** Diagnosis Date 1/1/2015 forward is a Reportable Malignancy

g) **All Thymoma Cases Diagnosed 1/1/2018 and later** are Reportable as “malignant thymoma”.

h) **Clarification for Reporting /2 and /3 Pancreatic Neoplasms** - The classification and reporting of tumors of the pancreas and of the pancreato-biliary system can be confusing in part due to the latest terminology associated with tumors arising within this body system, and complicated by the mixed nature of benign, borderline, in-situ and invasive neoplasms and various histologic subtypes associated with pancreato-biliary neoplasms. In 2010 the World Health Organization (WHO) published the latest WHO Classification of Tumors of the Pancreas. **ALL in-situ and invasive (malignant) neoplasms of the pancreas are reportable to FCDS.** However, some reportable neoplasms are associated with terminology registrars may not immediately recognize as reportable malignancy. FCDS is making every effort to capture these pancreato-biliary primary tumors early in the disease process as endoscopic ultrasound (EUS) and new imaging is improving diagnosis.

<table>
<thead>
<tr>
<th>Reportable</th>
<th>ICD-O-3</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>****/2</td>
<td>All Histologies with Behavior Code of /2 (in-situ)</td>
</tr>
<tr>
<td>Yes</td>
<td>****/3</td>
<td>All Histologies with Behavior Code of /3 (invasive)</td>
</tr>
<tr>
<td>Yes</td>
<td>8440/3</td>
<td>Cystadenocarcinoma of the pancreas</td>
</tr>
</tbody>
</table>
## SECTION I: GUIDELINES FOR CANCER DATA REPORTING

<table>
<thead>
<tr>
<th>Reportable</th>
<th>ICD-O-3</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>8150/3</td>
<td>Cystic Pancreatic Endocrine Neoplasm (CPEN)</td>
</tr>
<tr>
<td>Yes</td>
<td>8500/3</td>
<td>Infiltrating Duct Carcinoma of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8503/2</td>
<td>Intraductal Oncocytic Papillary Neoplasm (IOPN) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8453/2</td>
<td>Intraductal Papillary Mucinous Neoplasms (IPMN) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8453/3</td>
<td>Intraductal Papillary Mucinous Neoplasm (IPMN) with invasive carcinoma</td>
</tr>
<tr>
<td>Yes</td>
<td>8503/2</td>
<td>Intraductal Tubule-Papillary Neoplasm (ITPN) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8503/3</td>
<td>Intraductal Tubule-Papillary Neoplasm (ITPN) with invasive carcinoma</td>
</tr>
<tr>
<td>Yes</td>
<td>8470/2</td>
<td>Mucinous Cystic Neoplasm (MCN) of the pancreas with high-grade dysplasia</td>
</tr>
<tr>
<td>Yes</td>
<td>8470/2</td>
<td>Non-invasive Mucinous Cystic Neoplasm (MCN) of the pancreas with high-grade dysplasia</td>
</tr>
<tr>
<td>Yes</td>
<td>8470/3</td>
<td>Mucinous Cystadenocarcinoma of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8246/3</td>
<td>Neuroendocrine Carcinoma of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8240/3</td>
<td>Neuroendocrine Tumor, Grade 1 (NET GR1) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8249/3</td>
<td>Neuroendocrine Tumor, Grade 2 (NET GR2) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8471/3</td>
<td>Papillary Mucinous Cystadenocarcinoma of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8452/3</td>
<td>Solid Pseudo-Papillary Neoplasm (SPN) of the pancreas</td>
</tr>
<tr>
<td>Yes</td>
<td>8552/3*</td>
<td>Mixed acinar-ductal carcinoma</td>
</tr>
<tr>
<td>Yes</td>
<td>8163/2*</td>
<td>Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia</td>
</tr>
<tr>
<td>Yes</td>
<td>8163/3*</td>
<td>Pancreatobiliary-type carcinoma</td>
</tr>
<tr>
<td>No</td>
<td>n/a</td>
<td>Histologies with Behavior Code of /0 (benign)</td>
</tr>
<tr>
<td>No</td>
<td>n/a</td>
<td>Histologies with Behavior Code of /1 (borderline)</td>
</tr>
<tr>
<td>No</td>
<td>n/a</td>
<td>Serous cystadenomas, solid and cystic papillary (Hamoudi) tumors, lympho-epithelial cysts and simple cysts are all benign and not reportable</td>
</tr>
</tbody>
</table>

* New histology codes not yet implemented in the U.S. are still reportable – use histology 8500 or 8140

### References:

### i) Benign and Borderline Cancers

- **Benign** and **borderline** primary **intracranial** and **central nervous system** (CNS) tumors with a **behavior code of /0 or /1 in ICD-O-3** are reportable as of 01/01/2004.

#### Benign/Borderline Cancers diagnosed and/or treated before 1/1/2004 are not reportable to FCDS.

Benign and borderline tumors of intracranial glands include primary tumors of; pituitary gland, pineal gland, tumors of the craniopharyngeal duct, spinal and cerebral menigioma, and tumors of cranial nerves.


#### Benign and borderline neoplasms of the cranial bones (C41.0) are not reportable to FCDS.

**Sphenoid Wing Meningioma** is a Reportable Neoplasm beginning with 1/1/2004 diagnoses.

**Glomus Jugulare Tumors and Carotid Body Tumors** are head and neck cancers (tumors of the blood vessels of the neck). **They are not intracranial neoplasms and are “not reportable” to FCDS.**

**Pilocytic/Juvenile astrocytoma** is reportable; code the histology and behavior code 9421/3.
Table of Anatomic (Primary) Sites for Reportable Benign and Borderline Tumors of Intra-cranial and other central nervous system tumors.

<table>
<thead>
<tr>
<th>General Term</th>
<th>Anatomic Site</th>
<th>ICD-O-3 Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meninges</td>
<td>Cerebral meninges</td>
<td>C700</td>
</tr>
<tr>
<td></td>
<td>Spinal meninges</td>
<td>C701</td>
</tr>
<tr>
<td></td>
<td>Meninges, NOS</td>
<td>C709</td>
</tr>
<tr>
<td>Brain</td>
<td>Cerebrum</td>
<td>C710</td>
</tr>
<tr>
<td></td>
<td>Frontal lobe</td>
<td>C711</td>
</tr>
<tr>
<td></td>
<td>Temporal lobe</td>
<td>C712</td>
</tr>
<tr>
<td></td>
<td>Parietal lobe</td>
<td>C713</td>
</tr>
<tr>
<td></td>
<td>Occipital lobe</td>
<td>C714</td>
</tr>
<tr>
<td></td>
<td>Ventricles, NOS</td>
<td>C715</td>
</tr>
<tr>
<td></td>
<td>Cerebellum, NOS</td>
<td>C716</td>
</tr>
<tr>
<td></td>
<td>Brain stem</td>
<td>C717</td>
</tr>
<tr>
<td></td>
<td>Overlapping lesion of brain</td>
<td>C718</td>
</tr>
<tr>
<td></td>
<td>Brain, NOS</td>
<td>C719</td>
</tr>
<tr>
<td>Spinal cord, cranial nerves, and other parts of the central nervous system</td>
<td>Spinal cord</td>
<td>C720</td>
</tr>
<tr>
<td></td>
<td>Cauda equina</td>
<td>C721</td>
</tr>
<tr>
<td></td>
<td>Olfactory nerve</td>
<td>C722</td>
</tr>
<tr>
<td></td>
<td>Optic nerve</td>
<td>C723</td>
</tr>
<tr>
<td></td>
<td>Acoustic nerve</td>
<td>C724</td>
</tr>
<tr>
<td></td>
<td>Cranial nerve, NOS</td>
<td>C725</td>
</tr>
<tr>
<td></td>
<td>Overlapping lesion of brain and central nervous system</td>
<td>C728</td>
</tr>
<tr>
<td></td>
<td>Nervous system, NOS</td>
<td>C729</td>
</tr>
<tr>
<td>Pituitary gland, craniopharyngeal duct and pineal gland</td>
<td>Pituitary gland</td>
<td>C751</td>
</tr>
<tr>
<td></td>
<td>Craniopharyngeal duct</td>
<td>C752</td>
</tr>
<tr>
<td></td>
<td>Pineal gland</td>
<td>C753</td>
</tr>
</tbody>
</table>

4. Not Reportable Neoplasms

a) **Primary skin tumors** (C44._) with histology codes 8000-8110

Skin Cancers - Basal cell carcinoma and squamous cell carcinoma of non-genital skin sites are common malignancies. These tumors are not to be reported to FCDS, regardless of stage. All other malignant tumors of the skin must be reported including but not limited to malignant melanoma, Merkel cell carcinoma, lymphoma of skin, and other non-squamous and non-basal cell skin cancers. Only the following malignant neoplasms of the skin (C44.0-C44.9) are not reportable:

- M 8000 – M 8005 Neoplasm, malignant, NOS of the skin
- M 8010 – M 8046 Epithelial carcinoma, NOS of the skin
- M 8050 – M 8084 Papillary and squamous cell neoplasm of the skin
- M 8090 – M 8110 Basal cell carcinoma of the skin

b) **AIN III (8077/2) of the Perianal Skin** (C44.5) is not reportable.

c) **AIN III of anus or anal canal** (C21.0- C21.1) is reportable to FCDS.

d) **BIRADS category 4 and category 5 mammograms are not to be interpreted as a reportable "malignancy" for cancer registry purposes nor are they to be used to code the date of diagnosis should the patient subsequently have a malignancy confirmed.** If only the mammography report is available stating BIRADS 4 or BIRADS 5, this is not enough information to abstract and report the case to FCDS.

e) **LCIS is reportable to FCDS.** Lobular Carcinoma In-Situ (LCIS) was deemed ‘non-malignant’ by the AJCC in the most recent AJCC Cancer Staging Manual, 8th edition. The World Health Organization (WHO) still considers this histology to be in-situ malignancy.

Revised 2018
Operational rules are needed to ensure consistency in reporting multiple primary neoplasms. Basic factors include the anatomic site of origin of the neoplasm, the date of diagnosis, the histologic type of each neoplasm, the behavior of the neoplasm, and laterality. Please consult the attending physician if questions arise regarding the number of primary tumors.

In general, if there is a difference in the primary site where the neoplasm originates, it is fairly easy to determine whether it is a single or multiple primaries, regardless of dates of detection or differences in histology. Likewise, if there is a clear-cut difference in histology, other data such as the primary site and the date of detection are not essential to make this determination. Standardized rules have been developed and published to assist the registrar in making single versus multiple primary decisions.

2018 Multiple Primary and Histology Coding Rules for Solid Tumors and Database
The 2018 Multiple Primary and Histology Coding Rules for solid tumors contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder, and malignant and nonmalignant brain primaries. A separate set of rules addresses the specific and general rules for all other solid tumor sites. And, a special set of rules has been written for hematopoietic and lymphoid neoplasms. The multiple primary rules guide and standardize the process of determining the number of primary tumors or abstracts to be created. The histology rules contain detailed histology coding instructions. Registrars must refer to the 2018 Multiple Primary and Histology Coding Rules for general and cancer site-specific instructions. More information on these rules can be found on the NCI SEER website at http://seer.cancer.gov/tools/mphrules/index.html

2018 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Rules and Heme DB
The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the accompanying Hematopoietic Database replaced the ICD-O-3 Book as the primary coding reference for Myeloid and Lymphoid Neoplasms. At the same time, the 2018 rules and DB have replaced earlier versions of the DB as well as the historical February 2001 Single Versus Subsequent Primaries of Lymphatic and Hematopoietic Disease rules and foldout table. An on-line version of the new rules and database is available at: http://seer.cancer.gov/seertools/hemelymph. A desktop version is available for download at http://seer.cancer.gov/tools/heme/. Please be sure to use the most current version as these rules and codes replace all previous versions. IMPORTANT: DO NOT USE ICD-O-3 to code any histology 9590-9992. Use the most current Hematopoietic and Lymphoid Neoplasm MPH Rules Manual and Database as your primary reference.

6) Clarification of Reporting Requirements

a) Malignant Neoplasms/Benign tumors
A patient is considered to have a benign, borderline, or malignant neoplasm when so indicated by a recognized medical practitioner. In determining a diagnosis of cancer, a positive pathology report takes precedence over all other reports or statements. Many benign and borderline neoplasms of the brain and central nervous system are diagnosed based upon diagnostic imaging, only (CT, PET, MRI, etc.). Other cancers may be diagnosed by alternate means such as direct visualization (without biopsy) or a diagnosis may be based upon clinical evidence, alone. The data item “Diagnostic Confirmation” is used to identify the method of diagnosis for each case. The codes are to be used in a hierarchical order in most cases. In the absence of a positive pathology report, all information in the record must be assessed to determine whether or not the case is reportable and to identify the method used to establish (confirm) the diagnosis.

b) Clinically Diagnosed Cases Are Reportable
In the absence of a histologic or cytological confirmation of a reportable cancer, accession a case based on the clinical diagnosis (when a recognized medical practitioner says the patient has a cancer or carcinoma or when the patient is undergoing treatment for cancer that may not have been histologically or otherwise
confirmed). A clinical diagnosis may be recorded as part of the final diagnosis on the face sheet or other parts of the medical record. See Note and Exceptions below.

**Note:** A pathology report normally takes precedence over a clinical diagnosis. If the patient has a negative biopsy, the case would not be reported.

**Exception 1:** If the physician treats a patient for cancer in spite of the negative biopsy, abstract and report the case.

**Exception 2:** If enough time has passed that it is reasonable to assume that the physician has seen the negative pathology, but the clinician continues to call this a reportable disease, accession the case. A reasonable amount of time would be equal to or greater than 6 months.

c) **Ambiguous Terminology**

As part of the registry case-finding activities, all diagnostic reports should be reviewed to confirm whether a case is reportable. This includes pathology reports, bone marrow biopsy reports, autopsy reports, diagnostic imaging reports, and results from medical testing. If the terminology describing the diagnostic assessment is ambiguous, use the following guidelines to determine whether a particular case should be abstracted and reported to FCDS. Words or phrases that appear to be synonyms of these terms do not constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis.

In the absence of more definitive evidence, the following modifying terms, when applied to a neoplasm, should be interpreted as **diagnostic of cancer**:

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparent(ly)</td>
<td>consistent with neoplasm*</td>
<td>consistent with carcinoma</td>
</tr>
<tr>
<td>Appears</td>
<td>favor(s)</td>
<td>suspicious (for) mammography</td>
</tr>
<tr>
<td>comparable with</td>
<td>malignant appearing</td>
<td>mammography</td>
</tr>
<tr>
<td>compatible with</td>
<td>most likely</td>
<td>most likely</td>
</tr>
<tr>
<td></td>
<td></td>
<td>suspect(ed)</td>
</tr>
</tbody>
</table>

* use of the terms “neoplasm” and “tumor” begin with cases diagnosed 1/1/2004 and later and are to be used in conjunction with nonmalignant (benign or borderline ICD-O-3 behavior codes /0 or /1) primary intracranial and central nervous systems, only (C70.0-C72.9, C75.1-C75.3).

**Exception:** If cytology is reported as "suspicious," abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.

**Examples of Diagnostic Terms:**

**Example 1:** The inpatient discharge summary documents a chest x-ray **consistent with carcinoma** of the right upper lobe. The patient refused further work-up or treatment. **Consistent with carcinoma** is indicative of cancer.

**Example 2:** The mammogram report states **suspicious for malignancy**. **Suspicious for malignancy** is indicative of cancer.

**BIRADS Category 4 and Category 5 Mammograms** are not to be interpreted as a reportable "malignancy" for cancer registry purposes nor are they to be used to code the date of diagnosis should the patient subsequently have a malignancy confirmed. **BIRADS 4 or BIRADS 5** on Mammography without additional diagnostic confirmation (biopsy and/or imaging) to confirm cancer is not reportable to FCDS. **BIRADS 4 and BIRADS 5** are diagnostic imaging designations for highly suspicious for malignancy and malignancy on imaging. If only the mammography report is available stating **BIRADS 4 or BIRADS 5**, this is not enough information to abstract and report the case to FCDS.
Ambiguous Terms That Do Not Constitute a Diagnosis without additional information

The following modifying terms, when applied to a malignancy, should NOT be considered diagnostic of cancer without additional information such as treatment for cancer.

- Cannot be ruled out
- Questionable
- Equivocal
- Rule out
- Possible
- Suggests
- Potentially malignant
- Worrisome

Positive molecular marker or cytogenetic testing in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

In Situ and Invasive (Behavior codes /2 and /3)
- If an ambiguous term(s) precede a word that is synonymous with an in situ or invasive tumor (e.g.: cancer, carcinoma, malignant neoplasm, non-invasive cancer, etc.) the case is reportable. Abstract and report the case.

Example: The pathology report says: Prostate biopsy with markedly abnormal cells that are typical of adenocarcinoma.” Abstract and report the case.

Negative Example: The final diagnosis on the outpatient report reads: Rule out leukemia. Do not abstract or report the case. Do track that you reviewed the record and deemed the case not reportable. Be sure to include the reason the case is not reportable to FCDS so you do not have to re-review the case during the annual AHCA casefinding audit.

Discrepancies: If one section of the medical record(s) uses a reportable term such as “apparently” and another section of the medical record(s) uses a term that is not on the reportable list, accept the reportable term and abstract the case.

Exception: Do not abstract a case based on suspicious cytology, alone. The case is to be abstracted only if proven by positive cytology or other diagnostic method including a physician’s clinical diagnosis. See the data item Diagnostic Confirmation for methods of diagnosis.

Note: If the word or an equivalent term does not appear on the reportable list or is not a form of a word on the reportable list, the term is not diagnostic of cancer. Do not report the case. Forms of the word are such as: “Favored” rather than Favor(s); “appeared to be” rather than appears. Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable.

Use these terms when screening diagnoses on pathology reports, operative reports, imaging/scans, and other diagnostic testing other than tumor markers.

Note: If the ambiguous diagnosis is proven to be not reportable by biopsy, cytology, or physician’s statement (cancer was ruled out as diagnosis), do not report the case.

Example: Mammogram shows calcifications suspicious for intraductal carcinoma. The biopsy of the area surrounding the calcifications is negative for malignancy. Do not report the case.

Benign and borderline primary intracranial and CNS tumors

- Use the “Ambiguous Terms that are Reportable” list to identify benign and borderline primary intracranial and CNS tumors that are reportable.

- If any of the reportable ambiguous terms precede either the word “tumor” or the word “neoplasm,” the case is reportable. Abstract and report the case.
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

Example: The mass on the CT scan is consistent with pituitary tumor. Abstract and report the case.

- Discrepancies: If one section of the medical record(s) uses a reportable term such as “apparently” and another section of the medical record(s) uses a term that is not on the reportable list, accept the reportable term, abstract and report the case.

Exception: Do not abstract a case based only on suspicious cytology without additional confirmation of the presence of disease. The case is abstracted and reported if proven by positive cytology or other diagnostic methods including a physician’s clinical diagnosis. See the data item Diagnostic Confirmation for methods of diagnosis.

Note: If the word or an equivalent term does not appear on the reportable list or is not a form of a word on the reportable list, the term is not diagnostic of cancer. Do not abstract the case. Forms of the word are such as: “Favored” rather than Favor(s); “appeared to be” rather than appears. Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable.

- Use these terms when screening diagnoses on pathology reports, scans, ultrasounds, and other diagnostic testing other than tumor markers.

Note: If the ambiguous diagnosis is proven to be not reportable by biopsy, cytology, or physician’s statement, do not abstract or report the case.

d) Outpatient/Ambulatory Care Only Cases

There must be sufficient documentation in the medical chart (positive radiology report, positive pathology report, physician statement, etc.) that definitively establishes that the patient either has active malignancy and/or is currently undergoing therapy for malignancy. If insufficient documentation exists in the medical chart, do not abstract the case.

e) Non-Analytic Cases

The American College of Surgeons/Commission on Cancer does not require accredited facilities to abstract non-analytic cases. However, FCDS does require the collection and reporting of ALL cases that meet the FCDS reporting requirements, regardless of Class of Case. Many CoC Non-Analytic Cases are BOTH Reportable and Analytic to FCDS and NPCR. Please report as complete a case history as possible for these.

f) Historical Cases

The American College of Surgeons/Commission on Cancer does not require accredited facilities to abstract historical cases. However, FCDS does require the collection and reporting of certain historical cancers even when the patient has no evidence the historical cancer is “active”.

Patients diagnosed with any cancer during their lifetime are many times more likely to develop new cancers. It is important for researchers to know the number and types of any and all cancers each patient has had during his/her lifetime in order to effectively research and evaluate cancer incidence.

If a patient has had at least one primary reportable neoplasm that is currently active or under treatment, all other primary reportable neoplasms the patient has ever had (active or inactive), regardless of the date of diagnosis, must be reported. Each case of cancer must be abstracted and reported separately.

Information about the previous (historical) primary(s) may be sketchy. The abstractor should attempt to complete an abstract with as much information as is available in the medical record.
If the patient does not have any reportable neoplasms, active or under treatment, no other primary neoplasms the patient has ever had need to be reported.

**NOTE: DO NOT INCLUDE OBSOLETE HISTOLOGY CODES** of any kind when reporting historical cases regardless of method for reporting these cases (Minimal Historical Grid or Full Abstract). The case will fail edits. This includes obsolete histology codes (do not include), obsolete treatment codes (do not include), obsolete staging system or stage code(s), etc. Abstract these cases according to the most current standards.

g) **Multi-Facility Reporting (shared cases)**

FCDS requires that any cancer case that meets FCDS case reporting requirements must be submitted by every facility providing services to the patient. Therefore, facilities that are members of shared, combined or joint cancer registries and/or cancer programs must report each cancer case seen in each facility separately unless approved to do so by the Florida Department of Health and FCDS.

h) **Responsibility for Reporting**

It is the responsibility of the custodian of the medical record or the facility that is administering care to report the case to FCDS. FCDS reviews the Agency for Health Care Administration (AHCA) cancer patient data annually as a retrospective quality control completeness audit. The AHCA database provides an after-the-fact case finding mechanism; ensuring cancer cases that have been reported to AHCA are also included in the FCDS database.

i) **Annual Reporting Deadline – June 30th**

The June 30th Deadline is an annual milestone for cancer reporting in Florida. Florida law requires that all cancer cases diagnosed/treated for cancer, having a cancer-related health visit while undergoing cancer treatment, or having any evidence of disease at the time of encounter must be abstracted and transmitted to FCDS within 6 months of the date of first encounter for cancer.

FCDS reinforces the 6-month reporting standard with a June 30th Deadline each year.

Reporting Compliance and Data Quality Reports are run following the annual June 30th Deadline.

Facilities not in compliance with the 6-month reporting rule will be notified by FCDS of the delinquency. Each facility will be asked to develop a remedial plan to bring the facility back into compliance with state statutes. The plan must also include a statement indicating how the facility plans to stay in compliance once the current reporting year has been completed and compliance has been reached for the year in question.

If no action is taken or delinquency continues, FCDS will notify the Florida Department of Health that the facility is non-compliant and further action will be taken. Any remediation or other action plan must be approved by the Florida Department of Health and FCDS. FCDS will monitor the plan.
## SECTION I: GUIDELINES FOR CANCER DATA REPORTING

### Table A: NAACCR Layout Version 18: Comparison of Reportable Cancers: FCDS, NPCR and CoC.

<table>
<thead>
<tr>
<th>Reportable Diagnoses</th>
<th>FCDS</th>
<th>NPCR</th>
<th>CoC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Behavior code of 2 or 3 in ICD-O-3 (includes LIN III, VIN III, VAIN III) or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) and any updates. 2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* as defined in Section I of DAM.</td>
<td>1. Behavior code of 2 or 3 in ICD-O-3 (includes VIN III, VAIN III, AIN III); or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) and any updates. 2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in Table 3.</td>
<td>1. Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008:39). 2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in Table 3.</td>
<td></td>
</tr>
</tbody>
</table>

### Exceptions (not reportable)


### Historical Neoplasms

If a patient has at least one primary reportable neoplasm which is active or under treatment, all other primary reportable neoplasms the patient has ever had (active or inactive), regardless of the date of diagnosis, must be reported. Not included unless patient has evidence of this neoplasm (active disease). Not included unless patient has evidence of this neoplasm (active disease). |

### Multiple Primary Rules

2018 Multiple Primary and Histology Coding Rules and Database for Solid Tumors (most recent version). 2018 Multiple Primary and Histology Coding Rules and Database for Solid Tumors (most recent version). 2018 Multiple Primary and Histology Coding Rules and Database for Solid Tumors (most recent version). |

### Hematopoietic and Lymphoid Neoplasm Rules


### Ambiguous Terminology Considered as Diagnostic of Cancer**

| apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of |
|---|---|---|---|---|---|---|
| Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician’s clinical impression supports the cytology findings, do not consider as diagnostic of cancer. |

### Ambiguous Terminology NOT Considered as Diagnostic of Cancer**

| cannot be ruled out equivocal possible potentially malignant questionable rule out suggests worrisome |
|---|---|---|---|---|---|---|
| Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician’s clinical impression supports the cytology findings, do not consider as diagnostic of cancer. |

* Juvenile astrocytoma is reported as 9421/3.
** Do not substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable.” Do not substitute “likely” for “most likely.”

Revised 2018
Table 3. Primary Site Codes for Non-Malignant Primary Intracranial and Central Nervous System Tumors (non-malignant primary intracranial and central nervous system tumors with a behavior code of 0 or 1 [benign/borderline] are reportable regardless of histologic type for these topography codes). The CDC Brain Tumor Guide entitled, “Data Collection of Primary Central Nervous System Tumors” is available for reference @ [http://www.cdc.gov/cancer/npcr/pdf/btr/brain_tumor_guide.pdf](http://www.cdc.gov/cancer/npcr/pdf/btr/brain_tumor_guide.pdf)

**Reference** Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Sixteenth Edition Version 18 – Chapter III: Standards for Tumor Inclusion and Reportability

<table>
<thead>
<tr>
<th>Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C70.0</td>
<td>Meninges</td>
</tr>
<tr>
<td>C70.1</td>
<td>Cerebral Meninges</td>
</tr>
<tr>
<td>C70.9</td>
<td>Spinal meninges</td>
</tr>
<tr>
<td></td>
<td>Meninges, NOS</td>
</tr>
<tr>
<td>C71.0</td>
<td>Brain</td>
</tr>
<tr>
<td>C71.1</td>
<td>Cerebrum</td>
</tr>
<tr>
<td>C71.2</td>
<td>Frontal lobe</td>
</tr>
<tr>
<td>C71.3</td>
<td>Temporal lobe</td>
</tr>
<tr>
<td>C71.4</td>
<td>Parietal lobe</td>
</tr>
<tr>
<td>C71.5</td>
<td>Occipital lobe</td>
</tr>
<tr>
<td>C71.6</td>
<td>Ventricle, NOS</td>
</tr>
<tr>
<td>C71.7</td>
<td>Cerebellum, NOS</td>
</tr>
<tr>
<td>C71.8</td>
<td>Brain stem</td>
</tr>
<tr>
<td>C71.9</td>
<td>Overlapping lesion of brain</td>
</tr>
<tr>
<td></td>
<td>Brain, NOS</td>
</tr>
<tr>
<td>C72.0</td>
<td>Spinal Cord, Cranial Nerves, and Other Parts of the Central Nervous System</td>
</tr>
<tr>
<td>C72.1</td>
<td>Nervous System</td>
</tr>
<tr>
<td>C72.2</td>
<td>Spinal cord</td>
</tr>
<tr>
<td>C72.3</td>
<td>Cauda equina</td>
</tr>
<tr>
<td>C72.4</td>
<td>Olfactory nerve</td>
</tr>
<tr>
<td>C72.5</td>
<td>Optic nerve</td>
</tr>
<tr>
<td>C72.8</td>
<td>Acoustic nerve</td>
</tr>
<tr>
<td>C72.9</td>
<td>Cranial nerve, NOS</td>
</tr>
<tr>
<td></td>
<td>Overlapping lesion of brain and central nervous system</td>
</tr>
<tr>
<td></td>
<td>Nervous system, NOS</td>
</tr>
<tr>
<td>C75.1</td>
<td>Other Endocrine Glands and Related Structures</td>
</tr>
<tr>
<td>C75.2</td>
<td>Pituitary gland</td>
</tr>
<tr>
<td>C75.3</td>
<td>Craniohypophyseal duct</td>
</tr>
<tr>
<td></td>
<td>Pineal gland</td>
</tr>
</tbody>
</table>
B. CASEFINDING

Casefinding is the method used to identify new cancer cases, inpatient or outpatient. All facilities are responsible for complete casefinding for all patients seen at your facility regardless of type of service. It is important that the following multiple sources in the hospital be searched to keep missed reportable cases to a minimum. The procedure outlined below should be adapted to each individual facility:

1. **Pathology Reports** (biopsy specimen reports, surgical specimen reports, bone marrow biopsy, needle biopsy, cytology, autopsy, addenda, consultation reports, etc.)
2. **HIM/Medical Record Disease Indices or Unified Billing System Report – All Services** (All Patient Services - Inpatient and Outpatient, Clinics, Inpatient Hospice, etc.)
3. **Radiation Therapy** Department (patient logs and/or billing reports)
4. **Infusion or Treatment Center** (patient logs and/or billing reports)
5. **Outpatient Departments** (including cancer specialty clinics, chemotherapy clinics, infusion centers, day surgery, emergency room, medical oncology logs, etc.)
6. **Diagnostic Imaging** (Radiology) Department (MRI, CT, PET, x-ray, mammogram, etc.)

1) **Pathology Reports**

**ALL ANATOMIC (SURGICAL) PATHOLOGY REPORTS** (including reports from biopsy specimen, surgical resection specimen, bone marrow biopsy, needle biopsy and fine needle aspiration biopsy, diagnostic hematology, cytology and autopsy reports and all addenda) **for inpatients, outpatients and ambulatory care patients MUST be reviewed to determine whether or not a cancer is reportable.**

Pathology reports must also be reviewed at least annually to insure that no cases have been missed.

Pathology may be included in Casefinding Audits in addition to the Annual AHCA Casefinding Audit.

Most cancer patients have a biopsy or operative resection performed, nearly all of the reportable cases can be identified by pathology reports alone. Check with your pathology department to see if the department information system can be used to facilitate the review of these reports.

Electronic Copies of All Cancer-Related Pathology Reports MUST also be submitted electronically to FCDS under the FCDS E-Pathology Reporting Program. Please Contact Mike Thiry at FCDS.

2) **HIM/Medical Record Disease Index/Unified Billing System Report – All Services**

Every patient record with a reportable ICD-10-CM code (see Current Casefinding List) must be reviewed to determine whether or not the case meets FCDS criteria for case reporting. It is essential that all patient service areas be included in these reports. The FCDS Casefinding Lists have been pared down to only include diagnoses of active disease. Therefore, most cases on your list will need to be abstracted and reported.

ICD-10-CM and ICD-10-PCS were adopted as the U.S. standard on 10/1/2015. ICD-10-CM Casefinding List is included in this and previous FCDS DAM documents. Please ensure your facility IT staff has been given a copy of the ICD-10-CM list to avoid interruption in casefinding for the last quarter of calendar year 2015.

Upon review, if a patient is found not to have a malignancy as coded by the HIM/Medical Record or Billing Department or does not meet FCDS criteria for case reporting, the name should be added to the facility’s “Not Reportable List.” The list may be substituted with the facility “suspense” file based on available vendor tools.

The “Not Reportable List” is useful when FCDS is conducts casefinding audits based on AHCA data. Some facilities will save a “Not Reportable List” as an electronic file embedded within their software such as a “suspense” case and should include comments that the registrar reviewed the medical record and determined that the case does not meet reportable criteria. The “suspense” case should include documentation as to why the facility will not report the case either in text and/or using the FCDS AHCA Disposition Codes below.
3. **Radiation Therapy Department**

New patient registration rosters and radiation therapy summaries are excellent casefinding sources for patients treated with radiation. Unified Billing System Reports also can be used to identify these cases.

4. **Outpatient Departments**

New patient registration rosters for single-day surgery departments, oncology-related service areas (specialty clinics, chemotherapy clinics, infusion centers, day surgery, and other ambulatory care), outpatient departments (including outpatient diagnostic radiology and laboratory service areas) and emergency rooms are additional casefinding sources for patients seen only in an ambulatory care setting. Unified Billing System Reports also can be used to identify these cases.

5. **Diagnostic Imaging (Radiology) Department**

New patient registration rosters for patients receiving diagnostic imaging services (x-ray, CT scan, PET scan, MRI, or other imaging) are an excellent source for identifying new cancer cases.
ICD-10-CM CASEFINDING LIST FOR REPORTABLE TUMORS – Oct 1, 2017 and later encounters

The following ICD-10-CM list is to be used to identify potentially reportable tumors. Some ICD-10-CM codes contain conditions that are not reportable. These records should be reviewed and assessed individually to verify whether or not they are reportable to FCDS. ICD-10-CM implementation is expected nationwide October 1, 2017 for all hospitals. Appendix O contains a complete list of individual ICD-10-CM codes for reference.

<table>
<thead>
<tr>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C00._ - C43._</td>
<td>Malignant neoplasms</td>
</tr>
<tr>
<td>C4A._</td>
<td>Merkel cell carcinoma</td>
</tr>
<tr>
<td>C45._ - C96._</td>
<td>Malignant neoplasms</td>
</tr>
<tr>
<td>C49.A._</td>
<td>GI stromal tumor</td>
</tr>
<tr>
<td>C7A._</td>
<td>Malignant carcinoid tumors</td>
</tr>
<tr>
<td>C84.A._</td>
<td>Cutaneous T-cell lymphoma</td>
</tr>
<tr>
<td>C84.Z._</td>
<td>Other mature T/NK-cell lymphoma</td>
</tr>
<tr>
<td>C91.A._</td>
<td>Mature B-cell leukemia Burkitt-type</td>
</tr>
<tr>
<td>C91.Z._</td>
<td>Other lymphoid leukemia</td>
</tr>
<tr>
<td>C92.A._</td>
<td>Acute myeloid leukemia with multi-lineage dysplasia</td>
</tr>
<tr>
<td>C92.Z._</td>
<td>Other myeloid leukemia</td>
</tr>
<tr>
<td>C93.Z._</td>
<td>Other monocytic leukemia</td>
</tr>
<tr>
<td>C96.2._</td>
<td>Malignant mast cell neoplasms</td>
</tr>
<tr>
<td>C96.A._</td>
<td>Histiocytic sarcoma</td>
</tr>
<tr>
<td>C96.Z._</td>
<td>Other specified malignant neoplasm of lymphoid, hematopoietic and related tissue</td>
</tr>
<tr>
<td>D00._ - D09._</td>
<td>Carcinoma in situ (exclude: skin, cervix and prostate-- D04., D06. and D07.5)</td>
</tr>
<tr>
<td>D32._</td>
<td>Benign neoplasm of meninges (cerebral, spinal and unspecified)</td>
</tr>
<tr>
<td>D33._</td>
<td>Benign neoplasm of brain and other parts of central nervous system</td>
</tr>
<tr>
<td>D35.2, D35.4</td>
<td>Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland</td>
</tr>
<tr>
<td>D42.<em>, D43.</em></td>
<td>Neoplasm of uncertain or unknown behavior of meninges, brain, CNS</td>
</tr>
<tr>
<td>D44.3-D44.5</td>
<td>Neoplasm of uncertain behavior of pituitary gland, craniopharyngeal duct and pineal gland</td>
</tr>
<tr>
<td>D45</td>
<td>Polycythemia vera (9950/3)</td>
</tr>
<tr>
<td>D46._</td>
<td>Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)</td>
</tr>
<tr>
<td>D46.Z</td>
<td>Other myelodysplastic syndromes</td>
</tr>
<tr>
<td>D47._</td>
<td>Myeloproliferative diseases (9931, 9740, 9741, 9742, 9960, 9961, 9962, 9963, 9965, 9966, 9967, 9970, 9971, 9975, 9987)</td>
</tr>
<tr>
<td>D47.Z1</td>
<td>Post-transplant lymphoproliferative disorder (PTLD)</td>
</tr>
<tr>
<td>D49.6, D49.7</td>
<td>Neoplasm of unspecified behavior of brain, endocrine glands and other CNS</td>
</tr>
<tr>
<td>J91.0</td>
<td>Malignant Pleural Effusion</td>
</tr>
<tr>
<td>R18.0</td>
<td>Malignant ascites</td>
</tr>
<tr>
<td>Z51.0</td>
<td>Encounter for antineoplastic radiation therapy</td>
</tr>
<tr>
<td>Z51.1</td>
<td>Encounter for antineoplastic chemotherapy and immunotherapy</td>
</tr>
<tr>
<td>Z51.11</td>
<td>Encounter for antineoplastic chemotherapy</td>
</tr>
<tr>
<td>Z51.12</td>
<td>Encounter for antineoplastic immunotherapy</td>
</tr>
</tbody>
</table>

Note: Pilocytic/juvenile astrocytoma (M-9421) is reported with the behavior coded /3 (9421/3 not 9421/1).
C. **ABSTRACTING**

1. **Personnel Requirements – Abstractor Training and FCDS Abstractor Code**

**Abstractor Training:** Trained personnel must perform abstracting. FCDS provides basic incidence abstracting training via web-based modules free of charge and available 24 hours a day, 7 days a week. The 20 modules constitute one “course” in the FCDS learning management system, The Fundamental Learning Collaborative for the Cancer Surveillance Community. The 20 modules include over 1000 slides with sound overlay, practice exercises, and quizzes to monitor progress. The entire course takes from 40-80 hours to complete, depending on individual knowledge level at the start of the course. It is highly recommended that each student enter the course with a strong understanding of human anatomy and medical terminology. Modules are available at [https://fcds.med.miami.edu/inc/flccsc.shtml](https://fcds.med.miami.edu/inc/flccsc.shtml).

Every registrar/abstractor planning to work in the State of Florida is required to obtain an individual FCDS Abstractor Code. This code is assigned by FCDS to persons who successfully pass the FCDS Abstractor Code On-Line Examination, regardless of certification by NCRA as a CTR, experience in the registry industry, or other factors. As of January 1, 2013, any individual planning to acquire a New FCDS Abstractor Code or planning to Renew an Existing FCDS Abstractor Code must take and pass the FCDS Abstractor Code Exam. Registration for testing and real-time on-line testing can be found on the FCDS website.

The FCDS Abstractor Code Requirement has been FCDS Policy for many years and applies to every cancer registrar working in the state of Florida (CTR or non-CTR, Florida resident or out-of-state contractor, regardless of number of years’ experience). FCDS will not accept cases from individuals without an *Active/Current* FCDS Abstractor Code.

While the FCDS Abstractor Code Requirement Policy remains unchanged, the FCDS Abstractor Code Exam is a tool introduced to help FCDS expedite FCDS Abstractor Code approvals, renewals, and monitoring. Exams are short (20 multiple choice or T/F questions) with a variable mix of content questions weighted differently depending on whether this is an exam for a New FCDS Abstractor Code or Renewal of an existing FCDS Abstractor Code.

Questions are updated annually to ensure the most current standards are familiar to the tester. Questions are selected at random from a pool of more than 350 questions covering 7 major topic areas. No two exams will be alike.

Other training is available through SEER*Training, SEER*Educate, the Commission on Cancer, the American Joint Committee on Cancer, the National Cancer Registrars Association (NCRA), the Florida Cancer Registrars Association (FCRA), and the North American Association of Central Cancer Registries (NAACCR). Please see the annually updated document “2018 References and Resources for Cancer Registrars” published annually on our website and included as Appendix P in this manual.

**Fundamental Learning Collaborative for the Cancer Surveillance Community**

The Fundamental Learning Collaborative for the Cancer Surveillance Community (FLccSC) learning management system (LMS) was developed to provide cancer surveillance professionals in Florida a web-based educational platform. Courses are designed for students of all experience/skill levels. There are courses and modules for those that are new to the cancer surveillance field and continuing education courses for the seasoned professional. The FCDS Abstractor Code Test is one of the modules in FLccSC.

FLccSC is a cancer surveillance community educational collaboration. FLccSC is a web-based portal, which allows Central Cancer Registries (CCR) to customize a fully functioning state-specific Learning Management System (LMS). The Florida Cancer Data System and the South Carolina Central Cancer Registry developed FLccSC collaboratively. The initial development was funded by the respective State Departments of Health and the CDC/NPCR.

*Revised 2018*
Students access FLccSC from a link on each states CCR web-site. Once registered, the student will only see the LMS pages and content from their respective CCR. Once the student successfully completes an educational module, they will receive a Certificate of Completion including CEU where applicable.

FLccSC is a web-based educational collaborative LMS that is available 24/7. It is cost efficient in that the students do not have to travel to a central training site or purchase training materials.

FLccSC support includes access to a Help Desk for technical support and tutorials as a menu item on both the student site (frontend) and the e_Administration site (backend). The step by step tutorials details how to develop and maintain the CCR FLccSC site and educational content.

FLccSC allows educational material to be shared between and among CCRs at the e-Administrator's discretion.

There are many e-administrator tutorials and tutorials for students available on the FLccSC Site.

**FCDS Abstractor Code:** Every registrar/abstractor planning to work in the State of Florida is required to obtain an individual FCDS Abstractor Code. This code is assigned by FCDS to persons who successfully pass the FCDS Abstractor Code On-Line Examination, regardless of certification by NCRA as a CTR, experience in the registry industry, or other factors. As of January 1, 2013 any individual planning to acquire a New FCDS Abstractor Code or planning to renew an Existing FCDS Abstractor Code must take and pass the FCDS Abstractor Code Exam.

The FCDS Abstractor Code Requirement has been FCDS Policy for many years and applies to every cancer registrar working in the state of Florida (CTR or non-CTR, Florida resident, local or out-of-state contractor, interim service provider, or other registry staff - regardless of number of years’ experience or certification).

FCDS will not accept any cases from individuals without an *Active/Current* FCDS Abstractor Code.

Exams are short (20 multiple choice or T/F questions) with a variable mix of content questions.

Questions are updated annually to ensure the most current standards are familiar to the tester. Questions are selected at random from a pool of more than 350 questions covering 7 major topic areas. No two exams will be alike.

**The 7 topic areas include:**
- Florida Reporting Requirements
- General Abstracting Knowledge
- Anatomy and Physiology
- Primary Site/Histology/Grade
- Stage at Diagnosis (SS2018, SSDI, Grade)
- Latest Rule Changes (2018 Revisions to ICD-O-3 and Other Changes)
- Treatment and Survival

**Standard References Used for Testing:**
- FCDS DAM (current version)
- 2018 Casefinding List
- ICD-O-3 (including all errata and the 2010 and 2018 code updates)
- 2018 MPH Rules/Database for Solid Tumors (current)
- 2018 MPH Rules/Database for Hematopoietic/Lymphoid Neoplasms (current)
- SEER Summary Staging Manual 2018
- 2018 Site-Specific Data Items
- 2018 Grade Coding Manual
- SEER*Rx (current)
- SEER Self-Instruction Manuals (basics)
  ◇ Book 2 – Cancer Characteristics
  ◇ Book 3 – Tumor Registrar Vocabulary: Composition of Medical Terms
  ◇ Book 4 – Human Anatomy as Related to Tumor Formation
WHO NEEDS TO TAKE THE FCDS ABSTRACTOR CODE EXAM?

✓ Individuals hoping to acquire a **NEW** FCDS Abstractor Code will need to take the FCDS Abstractor Code Exam.

✓ Individuals with an **ACTIVE** (not yet expired) FCDS Abstractor Code can take the FCDS Abstractor Code Exam 30 days before expiration or once their code has expired.

✓ Individuals with an **EXPIRED** FCDS Abstractor Code will be required to take the FCDS Abstractor Code Exam **each** year in order to keep their FCDS Abstractor Code current and to renew their individual FCDS Abstractor Code, annually.

✓ If an individual’s FCDS Abstractor Code has been expired for greater than 2 years, the individual must re-take and pass the FCDS Abstractor Code Exam.

2. **Case Abstracting Requirements – Timeliness**

Individual cases **must be abstracted no later than six months** after the date of first contact with the reporting facility. The only exceptions to this reporting timeline are the free-standing ambulatory surgical centers who are reporting under the Ambulatory Centers Cancer Reporting Program.

Cases may be abstracted earlier than six months after the date of first contact, but only if the required information regarding first course of therapy is available and complete.

**DO NOT SEND INCOMPLETE RQRS (Rapid Quality Reporting System) CASES TO FCDS.**

All cases meeting the reporting requirements outlined in Section I.A must be abstracted following the guidelines set forth in Section II of this document. Questions regarding the interpretation of individual data items should be referred to the FCDS office.

**Note:** The ACoS CoC changed CoC Cancer Program Standard 5.2 (abstracting timeliness) on 1/1/2014. This is a change for CoC Cancer Program Accreditation (only) and does not change the Florida 6-month reporting requirement or the FCDS June 30th Deadline.

**Why?** Florida Statute requires that cases be completely abstracted (all information must be included regarding the diagnosis, staging, first course of treatment, cancer progression or recurrence) within 6-months of first patient encounter for cancer at your facility.

**Do not send FCDS partial abstracts for ACoS CoC Rapid Quality Reporting System (RQRS).**

Note: The CoC FORDS Manual instructs registrars from CoC Programs that the data item “Date Case Completed” should not be filled in until the case has been completed and all data required have been abstracted/coded.

The case is “pending completion” until all first course treatment has been investigated and documented in the original abstract sent to FCDS and the final abstract that is sent to the NCDB.

All abstracts are required to pass the FCDS EDITS metafile.

3. **Not Reportable List**

A list of cases reviewed but not reported to FCDS (not reportable list) should be maintained by each reporting facility either in electronic or other format. This can be as part of your abstracting software maintained in your “suspense” file or in a separate document with easy access. A sample form is included.
at the end of this Section. Any patient encounter that appears on a facility casefinding list that does not meet the reporting requirements outlined in Section I should be recorded on the “Not Reportable List” with an explanation as to why the case will not be reported. FCDS suggests you also include the FCDS Disposition Code associated with the reason not reported to facilitate your annual AHCA Follow-Back activities.

The list should include the patient’s name, social security number, medical record number, date of birth, ICD-10-CM Cancer Diagnosis Code, admission date, and disposition code or reason they were not reported. The list may be kept in a paper notebook, spreadsheet, vendor software suspense file, or in any other easily accessible format. You may use the FCDS form or you may create your own.

Casefinding audits are performed annually at every reporting facility through annual case matching with the Florida Agency for Health Care Administration (AHCA) data files to assure completeness of reporting. The not reportable list will expedite resolution of cases that show up as ‘missed cases’ during these casefinding audits. Missed Cases Are Late Reported Cases – always.

Failure to keep the list will result in FCDS requesting that the reporting facility pull each ‘missed case’ record again and review whether or not it should have been reported to FCDS. An explanation must then be submitted to FCDS detailing any reason any case will not be reported to FCDS or the case must be abstracted and reported to FCDS.

FCDS Disposition Codes may be included in the file as reference for reason the case is not reportable.

4. Abstracting Non-Analytic and Historical Cases

Although the Commission on Cancer/American College of Surgeons (COC/ACoS) does not require accredited facilities to abstract non-analytic or historical cases, a population-based cancer registry such as FCDS must record ALL cancers meeting the FCDS reporting requirements, regardless of class of case, place of diagnosis or date of diagnosis. These cases require the same attention to detail and text as with any CoC “analytic” type case (abstracted and quality reviewed with the same rigorous data quality and documentation expectation). Include chronologic information about the cancer as available.

FCDS realizes that much of the information about the original diagnosis, staging and treatment of non-analytic and historical cancers may be unavailable or incomplete. The abstractor should attempt to complete each abstract with as much information as is available in the medical record.

5. Abstracting Historical Cases Optional Minimal Dataset
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

Historical case refers to a primary reportable neoplasm (malignant or benign/borderline brain/CNS tumors) that it is not active (no evidence of disease) and currently not receiving any treatment AND the patient is seen at the reporting facility for another cancer/benign reportable neoplasm that is active and/or undergoing treatment.

Duplicate Case Submissions (cases previously reported to FCDS) can be problematic when they are resent to FCDS as a new submission after having already been reported. Always reference and use the Facility Alpha Listing found in the FCDS Reports Menu with your facility reference date of 1/1/1981, regardless of CoC Changes to Your State of Florid Reference Date.

There are two methods for reporting a Historical Case: Do not report using obsolete histology codes.

FCDS will accept historical cases reported as full abstracts or reported using the minimal dataset.

DO NOT INCLUDE OBSOLETE CODES of any kind when reporting historical cases regardless of method for reporting these cases (Minimal Historical Grid or Full Abstract). This includes obsolete histology codes (do not include), obsolete treatment codes (do not include), obsolete staging system or stage code(s), etc. Abstract cases according to the current coding standard.

a. For every abstract submitted, the record layout will allow for the entry of up to five (5) historical cases. The fields required for each of the five cases include:

1. Sequence Number
2. Diagnosis Date
3. Primary Site (ICD-O-3)
4. Histology (ICD-O-3)
5. Behavior (ICD-O-3)
6. Laterality
7. State of Residence at Diagnosis (State Abbreviation)
8. County of Residence at Diagnosis (FIPS County Code)
9. Schema Discriminator 1
10. Schema Discriminator 2

b. These fields will be edited at time of transmission and will include Sequence Number and Diagnosis Date edit checks as well as State and County edit checks.

c. These fields should ONLY be used when abstracting a historical case with insufficient information.

d. A complete abstract MUST be reported to FCDS for cases with sufficient information in the patient's medical record or when the patient has evidence of the historical cancer at the time of patient encounter (persistent disease, progression of disease or disease recurrence – patient with evidence of this cancer at the time of patient encounter).

e. REMEMBER, the minimal dataset only applies to Class of Case 33 Historical Cases with insufficient information. All other Non-Analytical cases, including Class of Case 33 historical cases with sufficient information REQUIRE a full abstract be reported to FCDS.

f. Historical Cases should not include Unknown Primary Cancers (C80.9 or C76.*).

g. Quality Control for these cases will be increased and documentation supporting the minimal dataset may need to be provided.

6. Reporting Historical Cases in the State Specific fields
Duplicate Case Submissions (cases previously reported to FCDS) can be problematic when they are resubmitted to FCDS as a new submission after having already been reported. Always reference and use the Facility Alpha Listing found in the FCDS Reports Menu with your facility reference date of 1/1/1981, regardless of CoC Changes to Your State of Florida Reference Date.

a. Historical information must be completed starting with the eight fields in HISTORY1. Every additional historical case would use the next sequential group of eight fields (i.e. HISTORY2 through HISTORY5). No gaps in the groups can exist.

Examples:
One Historical Case – MUST use Historical #1 group of nine fields.
Two Historical Cases – MUST use Historical #1 and Historical #2 groups of nine fields.

In the example of Two Historical cases, if Historical #1 and Historical #3 groups of nine fields are populated, than abstract will not be accepted due to a gap in Historical #2 group.

b. When a particular group is selected (Historical #1), all nine fields must be filled.

Historical date must be completed in accordance with the current standards. If any of these fields are left blank, then the abstract and possibly the entire batch will be rejected.

Examples:
Historical #1: Sequence Number,
Historical #1: Dx Date,
Historical #1: Primary Site,
Historical #1: Histology,
Historical #1: Behavior,
Historical #1: Laterality,
Historical #1: Dx State Abbreviation,
Historical #1: Dx County FIPS
Historical #1: Schema Discriminator 1
Historical #1: Schema Discriminator 2

Once these historical groupings pass structure check edits, a full abstract will be generated from the data provided. The derived Historical abstracts will be subject to our full set of edit checks. If any failures exist, the abstract and batch will be rejected.

DO NOT INCLUDE OBSOLETE CODES when reporting historical cases regardless of method for reporting these cases (Minimal Historical Grid or Full Abstract). This includes obsolete histology codes (do not include), obsolete treatment codes (do not include), obsolete staging system or stage code(s), etc. Abstract cases according to current coding standard.

7. Annual Reporting Deadline – June 30th

The June 30th Deadline is an annual milestone for cancer reporting in Florida. Florida law requires that all cancer cases diagnosed/treated for cancer, having a cancer-related health visit while undergoing cancer treatment, or having any evidence of disease at the time of encounter must be abstracted and transmitted to FCDS within 6 months of the date of first encounter for cancer. FCDS reinforces the 6-month reporting standard with a June 30th Deadline each year.

Compliance and Data Quality Reports are run following the annual June 30th Deadline.

Facilities not in compliance with the 6-month reporting rule will be notified by FCDS of the delinquency. Each facility will be asked to develop a remedial plan to bring the facility back into compliance with state statutes with a plan to remain in compliance. If no action is taken or
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

delinquency continues, FCDS will notify the Florida Department of Health that the facility is non-
compliant and further action will be taken. Any remediation or other action plan must be approved
by the Florida Department of Health and FCDS. FCDS will monitor the plan.

8. Required/Recommended Desktop References – paper and/or electronic – current version
   Please refer to the document ‘2018 References and Resources for Cancer Registrars’ found in
   Appendix P of this manual.

REQUIRED DESKTOP REFERENCES

<table>
<thead>
<tr>
<th>REQUIRED REFERENCE</th>
<th>ORDERING INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current FCDS Data Acquisition Manual, 2018</strong></td>
<td>FCDS, Florida Cancer Data System&lt;br&gt;PO Box 016960 (D4-11)&lt;br&gt;Miami, FL 33101&lt;br&gt;<a href="http://fcds.med.miami.edu/inc/downloads.shtml">http://fcds.med.miami.edu/inc/downloads.shtml</a></td>
</tr>
<tr>
<td><strong>Current Multiple Primary and Histology Coding Rules for Solid Tumors</strong></td>
<td>National Cancer Institute, SEER Program, Bethesda, MD&lt;br&gt;Johnson CH, Peace S, Adamo P, et al. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD: 2007&lt;br&gt;<a href="http://seer.cancer.gov/registrars">http://seer.cancer.gov/registrars</a></td>
</tr>
<tr>
<td><strong>Current Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual</strong></td>
<td>Download latest version from the National Cancer Institute, SEER Program, Bethesda, MD&lt;br&gt;<a href="http://seer.cancer.gov/registrars">http://seer.cancer.gov/registrars</a></td>
</tr>
<tr>
<td><strong>2018 SEER Summary Staging Manual</strong></td>
<td>Download e-version (no printed versions available)&lt;br&gt;National Cancer Institute, SEER Program, Bethesda, MD&lt;br&gt;<a href="http://seer.cancer.gov/registrars">http://seer.cancer.gov/registrars</a></td>
</tr>
<tr>
<td><strong>2018 Site-Specific Data Items Manual (SSDI Manual), SSDI Coding Instructions,</strong></td>
<td><a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a></td>
</tr>
<tr>
<td><strong>2018 Site-Specific Data Items Manual (SSDI Manual), SSDI Coding Instructions,</strong></td>
<td><a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a></td>
</tr>
<tr>
<td><strong>2018 Grade Manual, Grade Coding Instructions and Tables, and Grade Coding</strong></td>
<td><a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a></td>
</tr>
<tr>
<td><strong>Current SEER*Rx – Interactive Drug Database</strong></td>
<td>National Cancer Institute, Surveillance, Epidemiology and End Results Program, Bethesda MD. Available for download at&lt;br&gt;<a href="http://seer.cancer.gov/registrars/">http://seer.cancer.gov/registrars/</a></td>
</tr>
</tbody>
</table>
## RECOMMENDED DESC REFERENCE

<table>
<thead>
<tr>
<th>RECOMMENDED BOOK</th>
<th>ORDERING INFORMATION</th>
</tr>
</thead>
</table>
| **2018 CoC Standards for Oncology Registry Entry (CoC STORE)** - | American College of Surgeons (ACS)  
55 East Erie Street  
Chicago, IL 60611-2797  
| **AJCC Cancer Staging Manual, 8th ed.**  
| **CA: A Cancer Journal for Clinicians** | Lippincott Williams & Wilkins Publishers  
P.O. Box 1600  
Hagerstown, MD 21741-9910  
| **Cancer Principles and Practice of Oncology, 10th edition** | Lippincott Williams & Wilkins Publishers  
227 East Washington Square  
Philadelphia, PA 19106-3780  
ISBN-10: 1451192940  
4050 Westmark Drive, PO Box 1840  
Dubuque, IA 52004-1840  
1-(800) 228-0810  
[www.kendallhunt.com/ncra](http://www.kendallhunt.com/ncra)  
| **American Cancer Society Textbook of Clinical Oncology** | American Cancer Society  
Vermont Division, Inc.  
13 Loomis Street  
Montpelier, VT 05602  
[http://www.cancer.org](http://www.cancer.org)  
ISBN-10: 0944235077 |
| **Registry Plus Online Help** | Download the free desktop reference, Registry Plus Online Help at [http://www.cdc.gov/cancer/npcr](http://www.cdc.gov/cancer/npcr)  
Online Help is an interactive tool that incorporates many of the references above and is maintained by the CDC. The Registry Plus Online Help application includes fully indexed versions of the FORDS Manual, Collaborative Stage, and Multiple Primary and Histology Coding manuals as well as the NAACCR Data Dictionary, the SEER Coding Manual and the ICD-O-3. |
| **NAACCR Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, current edition** | North American Association of Central Cancer Registries, Inc. (NAACCR)  
2121 West White Oaks Drive, Suite B  
Springfield, Illinois 62704-7412  
Phone: (217) 698-0800 Fax: (217) 698-0188  
[http://www.naaccr.org](http://www.naaccr.org) |
D. DATA TRANSMISSION (Batched Records or Single Case Entry plus Edits/Corrections/QC)

ALL CASES MUST BE TRANSMITTED TO FCDS ELECTRONICALLY using the FCDS secure information and data sharing portal: the FCDS IDEA, and in accordance with all FCDS Data Submission Policies and Procedures and Transfer Protocols. Appendix Q for FAQs on FCDS IDEA.

RELEASE OF INFORMATION – FCDS will not release any patient information directly to any contractor due to liability and confidentiality issues regarding contractual agreements not involving FCDS. Furthermore, new guidelines set forth under HIPAA (Health Insurance Portability and Accountability Act) have introduced additional restrictions regarding releasing and re-releasing patient information under many circumstances. FCDS understands that this policy may present some challenges to some contractors. Any contract between a healthcare facility and a private contractor where FCDS is not a party to the contract cannot include allowances for FCDS to release patient information to anyone other than the reporting facility.

Contractors must make arrangements with their clients (facilities) to forward any FCDS correspondence that includes patient information to them (contractor). This includes, but is not limited to edit discrepancies, quality control inquiries, verification of patient information, death certificate notification, AHCA casefinding audits, etc. Any discrepancies or omissions that are discovered after an abstract has been transmitted and processed will be posted to FCDS IDEA for review and/or correction. A SAMPLE FCDS Discrepancy Journal is provided at the end of this Section.

As a courtesy, FCDS will make every attempt to inform contractors of outgoing edits, quality control
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

inquiries, verification of patient information, death certificate notification, AHCA casefinding audits, etc. However, the contractor and the reporting facility are ultimately responsible for assuring these reports and inquiries reach the contractor through appropriate channels.

CONFIDENTIALITY - Patient information, personal health information, medical records and healthcare facility data are all confidential and continue to be a concern with regard to cancer and other disease reporting. Please do not fax or email patient information to FCDS. Also, please take care when discussing cases over the phone with FCDS staff.

DO NOT E-MAIL, FAX OR MAIL PATIENT INFORMATION (PHI) TO FCDS UNDER ANY CIRCUMSTANCES unless you are provided specific instructions for using our Secure Fax Service.

CONFIDENTIAL INFORMATION includes any HIPAA-defined Protected Health Information.

PHI information in the healthcare includes:
- Patient name, address including street, city, county, zip code and equivalent geo codes,
- Name of relatives,
- Name of employers,
- All elements of date pertaining to patient (ex-admission, discharge and birthdate)
- Telephone numbers
- Fax numbers
- Electronic email addresses
- Social Security number, medical record number,
- Health plan beneficiary number,
- Account number
- Certificate and license number,
- Any vehicle or other device serial number
- Web Universal Resource Locator (URL)
- Internet Protocol (IP) address number
- Finger or voice prints
- Photographic images

Quarterly Reporting

FCDS REQUIRES THAT FACILITIES TRANSMIT DATA AT LEAST QUARTERLY.

MONTHLY DATA SUBMISSION IS RECOMMENDED FOR LARGE FACILITIES (facilities reporting over 500 cases/year).

DO NOT SEND INCOMPLETE RQRS (Rapid Quality Reporting System) CASES TO FCDS.

1. Electronic Submissions

Record Layout
All data must be submitted in the current NAACCR Version (currently v18). The FCDS field positions and field lengths are standardized using the NAACCR transfer record layout, data definitions and data exchange guidelines. All fields identified in the FCDS Record Layout Appendix as Core (‘C’) must be completed. Historical cases may retain old standards.

3. Receipt on Upload

An Upload Receipt is generated after the upload is successfully transmitted. Please validate that the Upload Receipt and the expected upload are the same number of cases as a quick easy QC check.

4. Data Acceptance Policy – FCDS EDITS

Batch submissions will be edited immediately during the upload process using the standard FCDS Revised 2018
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

EDITS metafile. This metafile is published on the FCDS website and is available for use by software vendors and other interested parties who wish to run edits prior to data submission.

Each record must pass ALL inter and intra-item edits before acceptance by FCDS.

Records that require a NAACCR edit override (FORCE) will pass the edit check process and will be accepted. However, upon review at FCDS it may be determined the case does not meet the criteria for edit override (FORCE) and a correction may be made to the case.

For the cases requiring an edit override or Force, FCDS staff will review submitted text to determine if sufficient information has been provided to override the edit in question. If the information provided in text is insufficient, unclear, equivocal, incomplete or incorrect, the reporting facility will have two weeks from the time of case transmission to send FCDS the appropriate information from the patient’s medical records to support the code(s) assigned. FCDS QC Staff will use documentation provided to validate coding and set relevant override flag(s).

E. PSYCHIATRIC, MILITARY AND VETERANS ADMINISTRATION FACILITIES

United States military and Veterans Administration healthcare facilities are requested to report cancer under Rule 64D-3.006 of the Florida Administrative Code. While these institutions are not mandated to report, FCDS encourages them to voluntarily report their cancer cases in order to provide complete cancer incidence in Florida.

F. AMBULATORY SURGERY CENTERS

In July 1997, the Florida legislature amended state cancer reporting legislation to include cancer case reporting by ambulatory patient care facilities. The Florida Department of Health and FCDS agreed that in order to ease the burden of reporting by ambulatory centers FCDS would take on the responsibility of cancer case identification, the critical first step in the reporting of cancer cases.

Administrative Options for Reporting for Ambulatory Surgical Centers:

1. Facilities with a History of Reporting – Several ambulatory surgical centers already voluntarily report complete cancer cases to FCDS. Reporting by these facilities will continue as in the past. The FCDS notification of cases for cancer reporting for these facilities will actually be a quality control exercise. Cases identified through the notification process will be considered ‘Missed Cases’ and will need to be reported in a timely manner.

2. Annual reporting through the FCDS Notification of Cases (Annual AHCA Audit) - The AHCA discharge data from the surgical centers is matched with the complete FCDS Master-file database regardless of the type of cancer or the date of discharge. Records are matched on Social Security Number, Date of Birth, Sex, Race and County of Residence. Each AHCA record that does not match with a case in the FCDS Master-file is identified on the AHCA Unmatched Cancer Records Request listing for reporting.

3. Unmatched Ambulatory Surgery Center Cases are posted to the FCDS IDEA. Cases must be reviewed for reportability and abstracted using FCDS IDEA Single Entry. If the case is “not reportable” the appropriate AHCA Disposition Code must be entered in FCDS IDEA to explain why the facility will not report the case.
G. FREE-STANDING RADIATION THERAPY CENTERS

Those facilities that do not voluntarily report full cancer abstracts to FCDS will have to upload minimal data on all cancer patient encounters for casefinding using the FCDS IDEA. FCDS will match the cancer records identified by each facility against the FCDS Master file. Each record that does not match with a case in the FCDS Master file will be identified for reporting.

H. PRIVATE PHYSICIAN OFFICES

Practitioners licensed under Chapters 458, 459, 464, F.S., are required to report to the Florida Cancer Data System as required by Section 385.202, F.S., within six (6) months of each diagnosis and within six (6) months of the date of each treatment. Each physician office shall submit each cancer case report electronically. FCDS currently requires physician office (claims) reporting from medical oncology, hematology, urology, and other physician practices. Dermatology practices report under the Dermatology Reporting Module (abbreviated reporting mechanism designed to report skin cancers).

I. CLINICAL LABORATORY CANCER IDENTIFICATION PROGRAM

Every anatomic pathology laboratory that reads biopsy specimens and/or surgical resection specimens collected from patient encounters within the state of Florida MUST electronically submit the specified data for every malignant cancer case. This includes ALL hospital labs and ALL non-hospital labs.

Complete information, reporting specifications and pathology lab case report record layout can be found on the FCDS website at http://fcds.med.miami.edu. Each pathology laboratory has multiple submission choices; generating a tab delimited file from their existing database, using the web-based software provided by FCDS, generating an HL7 formatted file for download or generating an HL7 formatted file for transmission using PHINMS. Click on the PATH LAB icon then scroll down to the Path Labs File Layout. The document describes in detail the various formats that are acceptable to FCDS. The rest of the PATH LAB page includes important information for reference, including; the NAACCR/FCDS cancer terms, SNOMED codes and ICD-9 code files you should use to filter and select only the lab records that identify cancer as specified in these standard files.

J. FCDS RESPONSIBILITIES

1. Data Acquisition

In order to support the data acquisition aspect of the statewide registry, FCDS will:
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

a. Provide manuals, which specifically define data collection and reporting requirements,
b. Provide a data collection tool(s) and user manual(s) for electronic/web-based data submission,
c. Train facility staff and interested parties in incidence data collection via FCDS sponsored training programs (NAACCR Webinars), FCDS web-based training modules, teleconferences, FCDS web broadcasts or recorded educational events and programs. All FCDS-originated training materials and web broadcasts are recorded and available free on the FCDS website.
d. Provide specific routine reports to verify data submission and resolve data discrepancies.

2. Training and Education

FCDS develops, teaches, and supports a full range of Education and Training Options including:

- FCDS educational web broadcasts are organized up to 6 times a year or as needed.
- The FCDS On-Line web based Abstractor Training Course consisting of 20 modules and 1000 informational slides with voice-over recordings and testing is available on the FCDS website.
- FCDS hosts 12 NAACCR Educational Webinars at 7 host sites around the state each year.
- Additional resources are available and advertised through the FCDS Memo and via blast e-mail.

3. Quality Control

The primary objective of the Florida Cancer Data System (FCDS) is to maintain a high quality database of useable, timely, complete and accurate data for every case of cancer identified in the state of Florida.

a. **Completeness** is the extent to which all required cases have been reported to FCDS.

Completeness is assessed using:

1. Historical data from facilities
2. On-Site or Remote Access Casefinding Audits
3. Annual Linkage to Florida’s Agency for Health Care Administration statewide patient encounter files – AHCA Casefinding Audits (AHCA Match)

b. **Accuracy** is the extent to which the data submitted have been correctly coded and match the information contained in the medical record. Accuracy encompasses correct interpretation and application of coding rules and guidelines, identifies data entry and data submission errors and evaluates case correctness.

Accuracy is assessed using:

1. FCDS Abstractor Code Testing
2. FCDS Abstractor Code Annual Renewal Testing
3. Field-Item, Inter-Item and Intra-Item Data Edits
4. QC Visual Review Sampling of Every 25th Record
5. On-Site Re-Abstracting Audits
6. Remote Access Re-Abstracting Audits
7. Mail-In Re-Abstracting Audits
8. FCDS Management Reports

Accuracy involves how quickly each reporting facility submits cases to FCDS once a patient enters the health care system. The standard set forth by NAACCR, CDC/NPCR, ACOS/COC and FCDS is 95% of all new reportable cancer cases seen at any facility must be abstracted, submitted and any corrections for edit failures be completed within 6 months from the date of...
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

service. 100% of cases must be submitted by June 30 of any given year.

Timeliness is assessed using:

i. Admissions by Facility Report
ii. Facility Timeliness Report
iii. AHCA Audits

FCDS Data Quality/Quality Control Program Components

1. FCDS/Agency for Health Care Administration (AHCA) Casefinding Audits

FCDS staff will perform annual matching of the FCDS Master File to the Florida Agency for Health Care Administration (AHCA) files for both inpatient and outpatient/ambulatory patient encounters. FCDS will provide the reporting facility with an electronic list of Unmatched AHCA Cases (cases that appear in the AHCA files but have no matching record in the FCDS Master File) available on the FCDS website.

Consolidated AHCA and Vital Statistics Follow-Back (Casefinding Audits).

The Consolidated AHCA and Vital Statistics Follow-Back will be available via FCDS IDEA following the June 30 Reporting Deadline.

The facility abstractor then must compare the list of Unmatched AHCA Cases to the facility “Not Reportable List”. Cases that appear on the Unmatched AHCA Cases listing but do not appear on the “Not Reportable List” will need to be reviewed by the facility abstractor. Upon review, if any case is found to meet the cancer reporting requirements outlined in Section I, the case must be abstracted and reported to FCDS. These cases are a priority reporting item and must be abstracted as soon as possible. Please reference the AHCA Disposition Codes List for “reason not reported to FCDS”.

2. FCDS/Bureau of Vital Statistics Casefinding Audits (Death Clearance Audit)

FCDS staff will perform annual matching of the FCDS Master File to the Florida Bureau of Vital Statistics death files. FCDS will provide the reporting facility with a list of unmatched Vital Statistics cases (deaths) that show the place of death as the reporting facility.

Consolidated Vital Statistics and AHCA Follow-Back (Casefinding Audits).
The Integrated Vital Statistics and AHCA Follow-Back will be available via FCDS IDEA following the June 30 Reporting Deadline.

The facility abstractor will need to research these cases to determine if the patient did expire at the facility and whether or not the case meets the cancer reporting requirements. If any case is found to meet the reporting requirements, the case must be abstracted and reported to FCDS. For each case that will not be reported to FCDS or did not expire at the reporting facility, FCDS requires a brief statement be submitted that sufficiently explains why the case will not be reported. Please reference the Death Clearance Disposition Codes Listing below for “reason not reported to FCDS”.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Pending Follow Back</td>
</tr>
<tr>
<td>1</td>
<td>Missing Case - Case Abstracted &amp; Reported by Facility</td>
</tr>
<tr>
<td>2</td>
<td>NIR - Tumor was Not Malignant - Behavior = 0 or 1</td>
</tr>
<tr>
<td>3</td>
<td>NIR - Non-Reportable Skin Cancer - SlBenC44.4 and Morph &lt; 8000 to 8110</td>
</tr>
<tr>
<td>4</td>
<td>NIR - No Evidence of Cancer at This Time - NED</td>
</tr>
<tr>
<td>5</td>
<td>NIR - Consultation Only</td>
</tr>
<tr>
<td>6</td>
<td>NIR - Cancer Not Proven - Equivocal</td>
</tr>
<tr>
<td>7</td>
<td>Case Previously Reported to FCDS by this Facility</td>
</tr>
<tr>
<td>8</td>
<td>NIR - Outpatient Record with No Active Cancer Documented in Record</td>
</tr>
<tr>
<td>9</td>
<td>NIR - Incomplete Cancer or CNS III, VIN III, VAIN III, PIN III</td>
</tr>
<tr>
<td>10</td>
<td>NIR - Other</td>
</tr>
<tr>
<td>11</td>
<td>Case Abstracted by Facility but Not found in FCDS Masterfile</td>
</tr>
<tr>
<td>12</td>
<td>NIR - No Mention of Cancer in Medical Record</td>
</tr>
<tr>
<td>13</td>
<td>This Follow-back code no longer valid</td>
</tr>
<tr>
<td>14</td>
<td>NIR - Non-Reportable Malignant Prostatic Disease - Dx Prior to 2001</td>
</tr>
<tr>
<td>15</td>
<td>NIR - Case DX Prior to FCDS Reference Date - Same Cancer/Same Facility</td>
</tr>
<tr>
<td>16</td>
<td>NIR - Benign or Borderline Brain/CNS Tumor Dx Prior to 2004</td>
</tr>
<tr>
<td>20</td>
<td>Unknown if Reportable - No Record of this Patient at this Facility</td>
</tr>
<tr>
<td>21</td>
<td>Unknown if Reportable - Lost Medical Record</td>
</tr>
<tr>
<td>30</td>
<td>Unknown if Reportable - No Follow-Back Info ever Returned by Facility</td>
</tr>
<tr>
<td>40</td>
<td>NIR - Special Case - Other</td>
</tr>
<tr>
<td>41</td>
<td>This Vital Statistics Record Matches an AHCA Record - For FCDS Use Only</td>
</tr>
<tr>
<td>50</td>
<td>Hospice Case - Not a Hospital</td>
</tr>
<tr>
<td>51</td>
<td>Transitional Care Center - Not a Hospital</td>
</tr>
<tr>
<td>52</td>
<td>Not a Hospital, NOS</td>
</tr>
<tr>
<td>53</td>
<td>Cloaked Facility - No Records Available</td>
</tr>
<tr>
<td>54</td>
<td>Nursing Home Death or Disability Death, Not a Hospital Death</td>
</tr>
<tr>
<td>55</td>
<td>DCO Replaced by Non-DCO; For FCDS Use Only</td>
</tr>
<tr>
<td>56</td>
<td>Report Source 7 or 8 is corrected and does not link back to proper Pt.</td>
</tr>
<tr>
<td>57</td>
<td>Demographic information changed. Death Certificate linkage was lost.</td>
</tr>
</tbody>
</table>

3. **FCDS EDITS Metafile includes Field-Item, Inter-Item and Intra-Item Data Edits**

FCDS uses a standard EDITS Metafile that has been modified to meet Florida requirements. The FCDS EDITS Metafile can be found on the FCDS website as well as a master listing of changes by date. FCDS EDITS include data edits to validate codes, crosscheck related data items and records and check for blank fields. The Florida specific data edits were created for all Florida only fields as well as for common abstracting errors identified through re-abstracting audits. Edits are reviewed as needed (monthly). New edits are added as needed.

4. **QC Visual Review Sampling of Every 25th Record**

FCDS Quality Control staff visually reviews at least one in every 25th record submitted by each reporting facility. The Quality Control Visual Review is designed to facilitate visual editing of abstracted data. It allows a trained eye to detect inconsistent coding that electronic edit checks cannot identify; it is a tool to identify deficiencies in abstractors' understanding of abstracting concepts, data definitions and coding selections that may require additional training. The QC Abstract Review Case Selection Process is fully automated and randomly selects one of every 25th record processed, which accounts for 4% of cases being visually reviewed for accuracy. Each case selected is placed in a QC file ready for visual review by the FCDS QC staff. Records with discrepant data must be resolved by the reporting facilities through FCDS IDEA by making return comments on each case (agree/disagree/add documentation to support original coding/other rationale). The case is then reviewed again by FCDS QC staff (different staff than the original FCDS Reviewer) and a final decision is made based on all information available.
This three-step process provides the registry every opportunity to rebut identified “errors” or “deficiencies” in the abstract by having three CTR or CTR-eligible staff review each case and provide documented input to what they interpret from the documentation provided in the original abstract. This process also serves as an educational tool for new and experienced registrars regarding where they have deficiencies in their abstracting tool kit and what they should be doing when abstracting specific cases by providing comment on a case-by-case basis.

Registry Managers should always share results with staff member responsible for the original abstract. Otherwise, they will continue to make the same error without knowledge they are doing something incorrectly, inconsistently, or out of synch with national reporting standards and guidelines.

5. **On-Site or Remote Access Re-Abstracting Audits**

The FCDS Quality Control staff and/or outside contract agents working on behalf of FCDS will perform on-site or remote access review of abstracting procedures by auditing individual reports and/or entire medical records of cases previously submitted to FCDS. The data validation or re-abstracting audit serves to verify that coded data submitted to FCDS can be validated when compared to original source documents at the hospital or central registry level. Discrepant data are followed back to the originating institution for clarification.

Reconciliation of the Re-abstracting Audit: Key data items will be evaluated and any discrepancy noted between the auditor’s findings and the original abstract findings will be returned to the facility for reconciliation. If the auditor’s findings are disputed, documentation must be submitted to clarify the originally abstracted codes.

These audits allow assessment with regard to standardized interpretation of data definitions, coding rules and guidelines, policies and procedures and serve to identify areas that may require further education and training.

6. **Remote Access Re-Abstracting Audits**

FCDS may substitute On-Site Re-Abstracting Audits with Remote Access Re-Abstracting Audits. Should FCDS decide to perform Remote Online audits, facilities will be asked to make available pertinent reports from medical records and/or other data sources to FCDS for review or FCDS will utilize existing source documents used in routine reporting.

7. **FCDS Abstractor Code Policy**

Every registrar/abstractor planning to work in the State of Florida is required to obtain an individual FCDS Abstractor Code. This code is assigned by FCDS to persons who successfully pass the FCDS Abstractor Code On-Line Examination, regardless of certification by NCRA as a CTR, experience in the registry industry, or other factors. As of January 1, 2013, any individual planning to acquire a New FCDS Abstractor Code or planning to Renew an Existing FCDS Abstractor Code must take and pass the FCDS Abstractor Code Exam. Registration for testing and real-time on-line testing can be found on the FCDS website.

The FCDS Abstractor Code Requirement has been FCDS Policy for many years and applies to every cancer registrar working in the state of Florida (CTR or non-CTR, Florida resident or out-of-state contractor, regardless of number of years’ experience). FCDS will not accept cases from individuals without an Active/Current FCDS Abstractor Code.
While the FCDS Abstractor Code Requirement Policy remains unchanged, the FCDS Abstractor Code Exam is a tool introduced to help FCDS expedite FCDS Abstractor Code approvals, renewals, and monitoring. Exams are short (20 multiple choice or T/F questions) with a variable mix of content questions weighted differently depending on whether this is an exam for a New FCDS Abstractor Code or Renewal of an existing FCDS Abstractor Code.

Questions are updated annually to ensure the most current standards are familiar to the tester. Questions are selected at random from a pool of more than 350 questions covering 7 major topic areas. No two exams will be alike.

Before taking the exam, please read through and become familiar with the FCDS DAM to ensure you understand all of the Florida abstracting and data collection requirements. The current version FCDS DAM can be found on our website, [http://fcds.med.miami.edu](http://fcds.med.miami.edu). There are a few Florida-specific requirements critical to complete reporting in Florida that many out-of-state registrars miss – reporting of non-analytic cases and all sequences for historical cancers.

FCDS monitors use of individual codes and is alert to the practice of sharing abstractor codes for new staff, temporary staff, and even permanent staff.

Please be secure with your abstractor code, abstracted data, personal information, and all confidential materials.

A breach of confidentiality and/or of protected personal health information or PHI, also known as a HIPAA Violation, may result in substantial civil monetary penalties (up to $1.5 million in a single calendar year) and/or criminal penalties of up to 10 years in federal prison.

**Personal Health Information (PHI) includes:**

- Patient name, address including street, city, county, zip code and equivalent geo codes,
- Name of relatives,
- Name of employers,
- All elements of date pertaining to patient (ex-admission, discharge and birthdate)
- Telephone numbers
- Fax numbers
- Electronic email addresses
- Social Security number, medical record number,
- Health plan beneficiary number,
- Account number
- Certificate and license number,
- Any vehicle or other device serial number
- Web Universal Resource Locator (URL)
- Internet Protocol (IP) address number
- Finer or voice prints
- Photographic images

**FCDS Abstractor Code:** Every registrar/abstractor planning to work in the State of Florida is required to obtain an individual FCDS Abstractor Code. This code is assigned by FCDS to persons who successfully pass the FCDS Abstractor Code On-Line Examination, regardless of certification by NCRA as a CTR, experience in the registry industry, or other factors. As of January 1, 2013 any individual planning to acquire a New FCDS Abstractor Code or planning to renew an Existing FCDS Abstractor Code must take and pass the FCDS Abstractor Code Exam.

The FCDS Abstractor Code Requirement has been FCDS Policy for many years and applies to...
every cancer registrar working in the state of Florida (CTR or non-CTR, Florida resident, local or out-of-state contractor, interim service provider, or other registry staff - regardless of number of years’ experience or certification).

FCDS will not accept any cases from individuals without an Active/Current FCDS Abstractor Code.

Exams are short (20 multiple choice or T/F questions) with a variable mix of content questions.

Questions are updated annually to ensure the most current standards are familiar to the tester. Questions are selected at random from a pool of more than 350 questions covering 7 major topic areas. No two exams will be alike.

The 7 topic areas include:
✓ Florida Reporting Requirements
✓ General Abstracting Knowledge
✓ Anatomy and Physiology
✓ Primary Site/Histology/Grade
✓ Stage at Diagnosis (SS2018, SSDI, Grade)
✓ Latest Rule Changes (2018 Revisions to ICD-O-3 and Other Changes)
✓ Treatment and Survival

Standard References Used for Testing
• FCDS DAM (current version)
• 2018 Casefinding List
• ICD-O-3 (including all errata and the 2010 and 2018 code updates)
• 2018 MPH Rules/Database for Solid Tumors (current)
• 2018 MPH Rules/Database for Hematopoietic/Lymphoid Neoplasms (current)
• SEER Summary Staging Manual 2018
• 2018 Site-Specific Data Items
• 2018 Grade Coding Manual
• SEER*Rx (current)
• SEER Self-Instruction Manuals (basics)
  ◊ Book 2 – Cancer Characteristics
  ◊ Book 3 – Tumor Registrar Vocabulary: Composition of Medical Terms
  ◊ Book 4 – Human Anatomy as Related to Tumor Formation

WHO NEEDS TO TAKE THE FCDS ABSTRACTOR CODE EXAM?
✓ Individuals hoping to acquire a NEW FCDS Abstractor Code will need to take the New FCDS Abstractor Code Exam.

✓ If an individual’s FCDS Abstractor Code has been expired for greater than 2 years, the individual must re-apply and take and pass the New FCDS Abstractor Code Exam.

WHO NEEDS TO TAKE THE FCDS ABSTRACTOR CODE RENEWAL EXAM?
✓ Individuals with an ACTIVE (not yet expired) FCDS Abstractor Code will be required to take and pass the FCDS Abstractor Code Renewal Exam once their code has expired.

✓ Individuals with an EXPIRED FCDS Abstractor Code will be required to take the FCDS Abstractor Code Renewal Exam each year in order to keep their FCDS Abstractor Code current and to renew their individual FCDS Abstractor Code, annually.
3. **Case Abstracting Requirements – Timeliness**

Individual cases must be abstracted no later than six months after the date of first contact with the reporting facility. The only exceptions to this reporting timeline are the free-standing ambulatory surgical centers who are reporting under the Ambulatory Centers Cancer Reporting Program.

Cases may be abstracted earlier than six months after the date of first contact, but only if the required information regarding first course of therapy is available and complete.

**DO NOT SEND INCOMPLETE RQRS (Rapid Quality Reporting System) CASES TO FCDS.**

All cases meeting the reporting requirements outlined in Section I.A must be abstracted following the guidelines set forth in Section II of this document. Questions regarding the interpretation of individual data items should be referred to the FCDS office.

**Note:** The ACoS CoC changed CoC Cancer Program Standard 5.2 (abstracting timeliness) on 1/1/2014. This is a change for CoC Cancer Program Accreditation (only) and does not change the Florida 6-month reporting requirement or the FCDS June 30th Deadline.

*Why?* Florida Statute requires that cases be completely abstracted (all information must be included regarding the diagnosis, staging, first course of treatment, cancer progression or recurrence) within 6-months of first patient encounter for cancer at your facility.

**Do not send FCDS partial abstracts for ACoS CoC Rapid Quality Reporting System (RQRS).**

Note: The CoC FORDS Manual instructs registrars from CoC Programs that the data item “Date Case Completed” should not be filled in until the case has been completed and all data required have been abstracted/coded.

The case is “pending completion” until all first course treatment has been investigated and documented in the original abstract sent to FCDS and the final abstract that is sent to the NCDB.

All abstracts are required to pass the FCDS EDITS metafile.

8. **Admissions by Facilities Report**

FCDS Data Acquisition staff will review the Admissions by Facilities Report (an internal FCDS report) on a regular basis. This report makes a comparison of observed to expected numbers of cases reported by each facility for any time period requested. The report is based on a five-year historical summary of cases reported to FCDS by each facility. The ratio of observed to expected is reported as a percent of completeness. Either FCDS Staff or a representative of the Department of Health will notify facilities that have not reported the expected number of cases. These same data are included in the Quarterly Activity Report.

9. **Facility Timeliness Report**

FCDS Data Acquisition staff will review the Facility Timeliness Report on a regular basis. This report shows the average amount of time (in days) that it takes the reporting facility to submit a case to FCDS. It specifically; 1) calculates the difference between the date the reporting facility had the first contact with the patient and the date the case was abstracted, 2) calculates the difference between the date the case was abstracted and the date the case entered
the FCDS Master File, and 3) calculates the difference between the date the reporting facility first had contact with the patient and the date the case entered the FCDS Master File. The time between the date the reporting facility had contact with the patient and the date the case entered the FCDS Master File should be 180 days or less. These same data are included in the Quarterly Activity Report (see Section Forms).

10. Other Quality Control Studies and Audits

FCDS Quality Control staff will run quarterly reports to help identify areas of concern regarding reporting by individual facilities. These quarterly reports will be used to identify trends in case reporting that may need to be addressed at a facility or at the state level. For example, if a facility reports that 95% of their prostate cases are "unstaged" at the time of first contact with their facility there may be a problem with the abstractor’s understanding how to correctly interpret the field ‘FCDS Stage at First Contact’ and/or how to code it correctly. Similar analyses will be conducted for individual abstractors within the facility. The FCDS Quality Control staff will perform ad-hoc inquiries to the FCDS Master File when data requests are made. Any unusual data will be reviewed, and facility-abstracting staff may be requested to review individual cases to confirm the reporting of certain data items.

11. Facility Evaluation Report

The report is a graphical and numerical representation of the performance of a reporting facility over a given time period, detailing the three principles of data appraisal: Timeliness, Completeness and Accuracy.

13. FCDS Data Quality Indicator Report (DQIR)

The FCDS Data Quality Indicator Report is designed to provide feedback to registries on the completeness of case abstracts by examining the frequency of coding “unknown” or “ill-defined” values in key analytic data items. Data must meet rigorous national quality standards to be included in local, regional, state, and national cancer rates, reports to Congress, numerous surveillance-related publications and for registry certification.

The percent of “unknown” and “ill-defined” values is an indicator used in ranking Florida’s overall data quality and completeness of case reporting and is used when comparing Florida data to other states for overall data validity and reliability. These data are also early indicators of problem areas and areas where FCDS and local registries can improve upon cancer reporting as data are available. The report includes the Florida state and National distribution of “unknown” value used for comparison. The report uses data from analytic cases only.

*Note: This report is a scaled down model of a similar report the CDC National Program of Cancer Registries (NPCR) provides to Florida and each NPCR state as an assessment of our state-wide data.*

4. Data Requests

Before submitting an application for data you are strongly advised to review the new Automated Data Request instructional videos on the FCDS Data Request Web page. The tutorials explain how to navigate the DREAMS system. FCDS will no longer accept paper applications.
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

All data requests, regardless of the nature of the request, must be submitted to FCDS via the FCDS Data Request Automated Management System (DREAMS) module on the FCDS Website. All requests require an FCDS IDEA account; if a researcher does not have an FCDS IDEA account, he or she must first establish one. Please refer to the video ‘New IDEA User’ instructions on the Data Requests page of the FCDS Website.

Requests for data fall into five broad categories: (1) stat data, (2) tabular, (3) ad hoc, (4) data linkage and (5) hospital specific requests. There are specific procedures and fees for each category. This document provides a description for each of the categories as well as the fee. It is recommended that you read this document prior to filling out a DREAMS application.

There are instructional videos for each category of request. Please refer to the respective video on the FCDS Data Request web page before you begin your automated data request.

There are four separate and distinct entities involved in the data release approval process.
The number of entities involved in processing your request depends on several factors. Please refer to the specific category to see which entities are involved.

1) Florida Cancer Data System (FCDS) maintains and collects the data. FCDS performs data extracts after approvals are obtained from Florida DOH Cancer Registry Program (CRP) and if required from Florida DOH IRB (IRB).

2) Florida DOH Cancer Registry Program (CRP) decides what variables will or will not be released based on scientific merit and if variables are available that will meet the research needs of proposed research. The CRP will also decide whether or not the application will require Florida DOH IRB approval. It is essential that CRP approval is obtained prior to submitting for IRB approval.

3) Florida DOH IRB (IRB) reviews data applications to ensure it is ethical, and that participants are protected. The DOH IRB submission is outside of DREAMS.

4) Florida DOH Vital Statistics (VS) requires requestor to submit an application for approval of data items derived from death certificates. This is also outside DREAMS.

<table>
<thead>
<tr>
<th>Request Category</th>
<th>Approval Required by</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCDS</td>
<td>CRP</td>
</tr>
<tr>
<td>Stat</td>
<td></td>
</tr>
<tr>
<td>Tabular</td>
<td></td>
</tr>
<tr>
<td>Ad hoc</td>
<td></td>
</tr>
<tr>
<td>Linkage</td>
<td></td>
</tr>
<tr>
<td>Hospital Specific</td>
<td></td>
</tr>
</tbody>
</table>

1 may or may not be required, dependent on cell size, geographic level, source, variable(s) requested, etc.
2 reviewed to make sure that application complete and all information has been submitted before forwarding to the CPR for approval; not reviewed for scientific merit.

DATA REQUEST CATEGORIES

(1) Stat Data Request

Currently, FCDS provides one static dataset. This is a flat file. You will need some type of software to read in the data and analyze it (i.e. SAS, SPSS, SQL). For a complete list of variables contained in the dataset please refer to the “Variables available for request”. The list of variables in the Stat dataset file is fixed; it is strongly recommended that the requestor review the STAT layout.pdf prior to applying for a stat dataset.

The stat dataset is available free of charge; it contains county level case data for all sites, with many of the
SECTION I: GUIDELINES FOR CANCER DATA REPORTING
demographic variables collapsed into aggregate groups, i.e. age, race, marital status, etc. Refer to the Stat
layout.pdf for the variables included in the dataset and to the aggregated demographic variables. Please log
into DREAMS, select Stat Dataset and follow the submission instructions for this type of request.

Note: if your study requires record level data and the variables needed are not contained in the Stat dataset or
the aggregated groups will not meet your research needs, you will need to apply for an Ad Hoc/ type request.
Refer to the Ad hoc category for more information.

The Stat dataset is updated annually, with the most recent year being added as it becomes available.

FCDS will fill data requests for the Stat Dataset within 30 business days once the application is complete and
approved.

Please view the Stat Data Request Video prior to filling out the DREAMS application for this type of request.
Entities involved in approving the Stat dataset: FCDS.

(2) Tabular Data
These types of requests concern requests that require output in the form of tables or some specific statistical
output. An example of tabular data in a table could be a table such as

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td>Male</td>
</tr>
<tr>
<td>Rectum</td>
<td>Female</td>
</tr>
</tbody>
</table>

An example of tabular data could also be statistical output such as the mean age at diagnosis for brain cancer.

In an effort to protect the indirect identification of the patient, the "rule of ten" is applied; this rule suppresses
any counts containing fewer than 10 cases. Tabulated data may be released at or above the county code level
with a count of 10 or greater; for counts less than 10 or data below the county level approval will be required
from the CRP.

If data with counts fewer than 10 or below the county are needed, be sure to specify why it is needed in your
application; this will information will be needed by the CRP.

In addition, if you are requesting output in the form of tables, it is highly recommended that the requestor
submit templates of how the data is to be displayed.

FCDS will fill most tabular data requests within 30 business days once the application has been completed
and cost has been approved; tabular requests are invoiced by the hour. Refer to fee and billing procedure
section for additional information.

Please watch the Tabular Request Video prior to making this type of request.

Entities involved in approving tabular requests: FCDS and possibly CRP and VS. VS approval is only
required for those studies wanting to obtain variables derived from death certificates

(3) Ad hoc

In DREAMS this category is also referenced as Ad hoc/patient.

Research which requires record level data for secondary analysis or for patient contact will need to make this
type of request. Please review the variables available for release to make sure that FCDS has the variables that
will meet your research needs. Note: date of birth month and day are NOT releasable.
Note: approval for ad hoc/patient requests by Florida Department of Health (CRP & IRB) can take anywhere from 8 weeks to 18 months, depending on complexity of the request and thoroughness of the application. Please plan accordingly.

FCDS will fill most ad hoc/patient requests within 30 business days once the application has been completed and cost has been approved; ad hoc requests are invoiced by the hour; patient contact studies are invoiced according to the number of records extracted. Refer to fee and billing procedure section for additional information.

Please watch the Ad Hoc Request Video prior to making this type of request.

Entities involved in approving ad hoc/patient requests: CRP and possibly VS and IRB. The CRP will determine whether or not IRB approval is required. VS approval is only required for those studies wanting to obtain variables derived from death certificates.

(4) Data Linkage

A data linkage project is a request that involves linking internal FCDS data to an external data set.

Fields used in the linkage must be consistent in both data sets. The researcher should send FCDS the data in a fixed length ASCII file with the proper record layout and format. (Refer to Data Linkage Record Layout document). Any deviations from the record layout or format which require adjustment to the external data set will be charged to the requestor according to the fee schedule (Refer to Fees and Billing Procedure below).

At a minimum one of the following combinations are required to link records with FCDS:

1) First Name, Last Name, Sex, Date of Birth, Zip Code and Street Address
2) First Name, Last Name, Sex, Date of Birth, and Social Security Number

Additional information such as Middle Initial, Alias Name, Maiden Name, City, State, and Birthplace improve chances of successfully linking your records to FCDS and we strongly encourage you to submit these data items if available.

FCDS will fill data linkage requests within 8 weeks once the request and cost have been approved. Currently FCDS uses a combination of R and Stata for data linkages. Requests using other software can be considered but likely will result in additional fees and time, in which case the 8 week time frame does not apply and the researcher may be charged additional fees. A copy of the required record layout “Data Linkage Record Layout” is available under the “Data Request” link on the FCDS web site http://fcds.med.miami.edu.

Please note that all linkages must occur at the office of the Florida Cancer Data System. No offsite linkages are permitted.

Please watch the Data Linkage Request Video prior to making this type of request.

Entities involved in approving linkage requests: CRP and possibly VS and IRB. The CRP will determine whether or not IRB approval is required. VS approval is only required for those studies wanting to obtain variables derived from death certificates.

(5) Hospital Data Requests

Hospital data requests refer to requests for downloads for data which your facility has submitted.

You must be the Facility Access Administrator (FAA) in order to access this module.

You will be able to select the admission year(s) you would like to have extracted and the download will be
SECTION I: GUIDELINES FOR CANCER DATA REPORTING

available in the latest NAACCR version record layout.

Please watch the Hospital Specific Request Video prior to making this type of request.

Entities involved in approving hospital specific requests: FCDS

Fees and Billing Procedure

Most requests generate a fee. The FCDS does not receive additional funding to perform special, ad-hoc data analysis; therefore, actual costs are passed on to the research applicant. The fees are as follows:

- STAT Dataset - No Charge
- Minimum charge - $150.00
- Ad Hoc: Statistical analysis/programming/data coordination - $150.00 per hour

- Data Linkage:

<table>
<thead>
<tr>
<th>Number of Records</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sliding scale:</td>
<td></td>
</tr>
<tr>
<td>&lt;10,000</td>
<td>$3,000</td>
</tr>
<tr>
<td>10,000 – 24,999</td>
<td>$2,500 fee plus .05 cents per record</td>
</tr>
<tr>
<td>25,000 – 49,999</td>
<td>$3,000 fee plus .03 cents per record</td>
</tr>
<tr>
<td>50,000 – 99,999</td>
<td>$3,500 fee plus .02 cents per record</td>
</tr>
<tr>
<td>100,000 – 249,999</td>
<td>$4,000 fee plus .015 cents per record</td>
</tr>
<tr>
<td>250,000+</td>
<td>$5,000 fee plus .011 cents per record</td>
</tr>
</tbody>
</table>

- Geocoded & Patient Contact lists

<table>
<thead>
<tr>
<th>Number of Records</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sliding scale:</td>
<td></td>
</tr>
<tr>
<td>&lt;10,000</td>
<td>$1,500</td>
</tr>
<tr>
<td>10,000 – 24,999</td>
<td>$2,000</td>
</tr>
<tr>
<td>25,000 – 49,999</td>
<td>$2,500</td>
</tr>
<tr>
<td>50,000 – 99,999</td>
<td>$3,000</td>
</tr>
<tr>
<td>100,000 – 249,999</td>
<td>$3,500</td>
</tr>
<tr>
<td>250,000+</td>
<td>$4,000</td>
</tr>
</tbody>
</table>

Please note:
The billing procedure is as follows: once approval is granted and the data request is processed, the researcher will be notified in DREAMS when the dataset is available for download. An invoice will be downloaded along with the results of the data request or linkage from DREAMS. Payment may be made by check, purchase order or credit card.

Data linkage fees are charged for those projects involving the matching of an outside data source to the Florida Cancer Data System database.

Other Information:

Additional information such as published resources and statistics is available on the FCDS website: http://fcds.med.miami.edu.

All media requests should be directed to The Director of the FL DOH Office of Communications at 850-245-4111.

FCDS maintains a list of all published articles using FCDS Data. Please provide information on any scientific publications resulting from a data request. Thank you

Revised 2018
K. FCDS MANAGEMENT REPORTS

FCDS Quarterly Activity Status Report

This report summarizes the FCDS file activity for each facility on a quarterly basis. Every facility should have some file activity during every quarter of the year. The report documents information about the number and quality of cases submitted during the previous quarter, timeliness of reporting, and also provides an annual incidence and completeness summary, which compares observed-to-expected numbers of cases reported for the year. (See Forms Section)

FCDS Data Quality Indicator Report

This report is a scaled down model of a similar report the CDC National Program of Cancer Registries (NPCR) provides to Florida and each NPCR state as an assessment of state-wide data. The report reflects 5 years of data and examines the frequency of assignment of “unknown” or “ill-defined” values to key analysis variables over the course of the five-year period with comparison to national.

The percent of “unknown” and “ill-defined” values in certain variables is a data quality indicator used to rank Florida’s overall data quality and completeness of the data for each case reported and is used when comparing Florida data to other states for overall data reliability. These data are also indicators of problem areas where FCDS and local registries can improve upon cancer reporting as data are available.

Annual AHCA Unmatched Report

The AHCA Unmatched Report and subsequent follow-back procedures are used to assess casefinding completeness at the facility level.

Consolidated AHCA and Vital Statistics Follow-Back Reports (Casefinding Audits).

Consolidated AHCA and Vital Statistics Follow-Back Reports will be available via FCDS IDEA following the June 30 Reporting Deadline.

Annual Bureau of Vital Statistics Unmatched Report

FCDS staff will perform annual matching of the FCDS Master File to the Florida Bureau of Vital Statistics death files. FCDS will provide the reporting facility with a list of unmatched Vital Statistics cases (deaths) that show the place of death as the reporting facility.

Consolidated Vital Statistics and AHCA Follow-Back Reports (Casefinding Audits).

Consolidated Reports Vital Statistics and AHCA Follow-Back Reports will be available via FCDS IDEA following the June 30 Reporting Deadline.

FCDS EDITS Master List

This is a listing of all FCDS edits included in the latest FCDS EDITS Metafile and includes the edit number, edit category, and edit message. The current list can be found under Downloads on the FCDS website. This list is updated regularly and can be found on the FCDS Website under Downloads.

L. AWARDS

Jean Byers Memorial Award for Excellence in Cancer Registration
**SECTION I: GUIDELINES FOR CANCER DATA REPORTING**

**Pat Strait Award for Excellence in Cancer Registry Abstracting** – The Pat Strait Award for Excellence in Cancer Registry Abstracting is awarded to individuals who contribute to a facility achieving the annual Jean Byers Memorial Award.

Criteria for receipt of the Jean Byers Award and the Pat Strait Award are based on a standard set of criteria that meet or exceed the completeness, timeliness and accuracy requirements determined by FCDS and CDC. The criteria may change between years, depending on annual reporting conditions but generally are a factor of a combination of successful data quality metrics including; Reporting Deadline, percent of missed cases as determined using AHCA and Vital Statistics Matching and Follow-Back Results (missed cases cannot exceed 10% of the facility’s annual caseload), and other established data quality indicator metrics.

**M. FCDS GENERAL MAILING INSTRUCTIONS:**

**DO NOT MAIL ANY MATERIALS CONTAINING PERSONAL HEALTH INFORMATION**

In order to protect and properly handle all packages FCDS is making the following recommendations:

1. We ask that if you are mailing a package to FCDS use Federal Express, UPS, Airborne Express or any other type of courier service.

   a. The FCDS street address below must be used for courier packages:

      FCDS  
      University of Miami School of Medicine  
      1550 NW 10 AVE  
      Room 410  
      Miami, FL 33136

   Include the following text on a separate header page in the package.

   b. Always request a signature upon delivery.

   c. Make sure that the addressee at FCDS knows that she/he is to expect a package.

   d. Track the package to ensure that it has reached its destination. You may want to explore the e-mail tracking and notification features that the courier of choice offers.

2. For non-confidential information, if using US Postal Service, which may include Express mail, Priority mail, and Certified mail, you must use the FCDS PO Box address below:

   FCDS  
   University of Miami School of Medicine  
   PO BOX 016960 (D4-11)  
   Miami, FL 33101

3. All shipments must adhere to the FCDS Confidential Information Security Policy.

**N. CALENDAR/FORMS/TEMPLATES/SAMPLE REPORTS**

- FCDS Profile Modification Form - Sample
- FCDS Annual Reporting Calendar
- FCDS Discrepancy Journal - Sample
- Not Reportable List - Template
- FCDS Quarterly Activity Status Report – Sample
- FCDS Data Quality Indicator Report – Sample

Revised 2018